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Gastric cancer is the fourth most common cancer and the second most 
common cause of cancer related mortality worldwide. There are around 
870,000 new cases and 650,000 deaths per year. While surgery is the mainstay 
therapy for gastric cancer, chemotherapy may be used for advanced disease as 
an adjuvant or palliative treatment. 
It is known that heme oxygenase-1 (HO-1) expression is associated with a 
wide variety of pathological processes including cancers. HO-1 is the 
inducible isoform of heme oxygenase (HO), which is the rate-limiting 
enzyme in degradation of heme. HO-1 has complicated biological functions in 
vivo, including antioxidant, anti-inflammation, pro-angiogenesis and 
regulation of cell proliferation. Increased HO-1 could be found in chronic 
obstructive lung disease, hypoxic/ischemic injury, cancer, etc. We hypothesize 
that HO-1 may play a cytoprotective role in the chemotherapy of gastric 
cancer. Hence, our research is motivated by the question whether the 
sensitivity of gastric cancer to anti-cancer drug can be enhanced if HO-1 is 
inhibited; and if yes, what the possible mechanism is. 
Methods and Results 
We chose 5-Fluoracial (5-FU), a most widely used chemotherapeutic agent, as 
the trial drug. Gastric cancer cell lines, MKN28 with mutant p53 and MKN45 
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with wild p53 were treated with the HO-1 inhibitor ZnPP, 5-Fu or 5-FU plus 
ZnPP. Western blotting showed that HO-1 expression in both cells was 
significantly inhibited by ZnPP, while 5-FU up-regulated the expression of 
HO-1. The most important is that the induction of HO-1 by 5-FU could be 
offset by ZnPP. Subsequently, we assayed cell viability and apoptosis after the 
treatment with ZnPP, 5-FU or 5-FU plus ZnPP, using the MTT and TUNEL 
assays, respectively. From the triplicate results of MTT, we found that 
viability of both cells decreased significantly after the treatment with 5-FU 
plus ZnPP, as compared to that with 5-Fu only. Consistent with the MTT 
results, TUNEL showed that more apoptosis were induced by the combined 
treatment. Our study indicate that the cytotoxity of 5-FU to gastric cancer 
cells can be significantly enhanced after inhibiting the expression of HO-1, 
-which also proves that the increased expression of HO-1 in gastric cancer cells 
when treated with 5-FU is a cell protective response. The combination of 5-
FU and ZnPP produces a significantly additive cytotoxic effect on MKN28 
and MKN45 cells. 
To explore the mechanism responsibe for the additive cytotoxic effect of co-
treatment with 5-FU plus ZnPP, we assayed cell cycle and mitochondrial 
membrane potential by Flow Cytometry as well as a number of pro-apoptotic 
proteins involved in apoptosis pathways including mitochondrial-dependent 
ones ( cytochrome c, caspase-3) and mitochondrial-independent one 
(Apoptosis-inducing factor) by Western Blotting. 
XV 
The mitochondrial membrane potential was significantly reduced after 
the treatment with 5-FU in combination with the inhibition of HO-1 in 
MKN28 and MKN45, showing that apoptosis induced by 5-FU plus ZnPP in 
both types of cells is via a mitochondria-dependent pathway. 
Regarding assays for pro-apoptotic proteins, co-treatment with 5-FU and 
ZnPP activate caspase-3 in both cancer cell lines, demonstrating that the 
apoptosis is, at least partly, resulted from a caspase-dependent pathway in 
MKN28 and MKN45 cells. 
On the other hand, Cytochrome C in MKN45 and AIF in MKN28 were found 
to be translocated from mitochondria to the cytosol after the co-treatment with 
5FU and ZnPP. It suggests that the apoptosis in MKN45 caused by the co-
treatment takes place via a caspase-dependent pathway, whereas that in 
MKN28 involves both caspase-dependent and caspase-independent 
mechanism. 
Conclusions 
From our results, we conclude that (1) The induction of HO-1 by 5-Fu is a cell 
rescue response and the sensitivity of gastric cancer cells to 5-FU can be 
enhanced by HO-1 inhibitor ZnPP. (2)The anti-tumor function of 5-FU in 
combination with the inhibition of HO-1 in MKN28 and MKN45 is through a 
mitochondrial apoptosis pathway. (3)The treatment with 5-FU and ZnPP 
induces apoptosis via a caspase-dependent pathway in MKN45 while via both 
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caspase-dependent and caspase-independent pathway in MKN28. (4) 
Chemotherapeutic agents in combination with HO-1 inhibitors may be a 








我們注意到血紅素氧化酶-1 ( H 0 - 1 )的表達同很多病理包括癌症的發展 




癌症等病理狀態下H 0 - 1經常高表達。因此我們認爲H O - 1很可能參與癌 




我們選用經典抗癌葯 5 -箫尿啼淀 ( 5 - F U )作爲試驗化療劑，Z n P P作爲 
H 0 - 1的抑制劑。實驗使用的兩个胃癌細胞株，分別是帶變異型 p 5 3的 
M K N 2 8和帶野生型 p 5 3的M K N 4 5 �胃癌細胞分別接受 5 - F U , ZnPP, 
viii 
以及5-FU聯合ZnPP的藥物處理，然後進行實驗分析。Western Blotting 
的結果顯示Z n P P可以有效地抑制H 0 - 1的表達，5 - F U則是明顯的誘導 
H 0 - 1的表達，有意思的是，Z n P P可以相當程度的抵消5 - F U對H 0 - 1的 
誘導作用。檢測細胞活性的M T T試驗顯示5 - F U均可降低兩個細胞株的 
細胞存活率，同時，5 - F U與Z n P P的聯合治療可較單獨5 - F U更為大人 
降低兩株細胞的存活率。T U N E L結果顯示5 - F U與Z n P P的聯合治療比 
單獨的5 - F U治療更能誘導兩株細胞發生调亡。我們的這些實驗結果表 
明在抑制H 0-1的表達后，化療劑5 -FU對胃癌細胞的毒性顯著增加，同 





c a s p a s e - 3和錢粒體非依賴型通路相關蛋白如调亡誘導因子（A I F ) �我 
們的研究結果顯示兩株細胞在經過5 - F U與Z n P P的聯合治療后錢粒體膜 
電位有顯著降低，表明錢粒體依賴型调亡通路參與了對兩株細胞的聯合 
治療效應過程。Western Blotting顯示在經歷聯合治療后，pro-caspase-3 
蛋白比單獨5 - F U治療后明顯減少，表明聯合治療使得更多的c a s p a s e - 3 






過c a s p a s e s依賴型调亡通路並伴細胞色素C和c a s p a s e - 3的參與；而對 
MKN28的聯合療法則可能包含了兩條通路caspases依賴型调亡通路並伴 
caspase-3的參與以及caspases非依賴型通路伴AIF的參與。 
總之，我們的研究可概括為以下幾點：（1) 5 -FU在胃癌細胞株内誘導 
HO-1的表達是胃癌細胞的自我保護，抑制H0-1的表達可增強胃癌細胞 
對5 - F U治療的敏感性；（2 )錢粒體依賴型调亡通路參與5 - F U與Z n P P 
對M K N 2 8和M K N 4 5的聯合治療；（3 ) 5 - F U與Z n P P對M K N 4 5的聯 
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Chapter One: Introduction 
1 
1.1. Epidemiology of Gastric Cancer 
Gastric cancer is the fourth most common cancer following lung cancer, 
breast cancer and colorectal cancer and the second most common death-
related cancer worldwide(Ikeda, Saku et al.). According to a recent global 
V 
report (Ferlay J et al, 2002), the age-standardized incidence rates (ASR) of 
gastric cancer worldwide in 2002 were 22.0 and 10.4 for males and 
females, while mortality rate was 16.3 and 7.9 for males and females. 
Gastric cancer cases show a geographic distribution with around two-
thirds occurring in less developed regions (Fig 1.1 and Fig 1.2)，such as 
Eastern Asia, Central America, South America and Eastern Europe. The 
highest ASR is present in Korea (69.7), followed by Japan (62.0). China 
ranks the sixth with an ASR of 41.4. In China, gastric cancer is the second 
most common cancer after lung cancer and the third most common cancer 
leading to death, only after lung cancer and liver cancer (Fig.1.3.). The 
prognosis of gastric cancer is still poor. 5-year survival rate for gastric 
cancer is currently good in Japan (52%) (Parkin 2001) after they began to 
‘ perform mass screening programs by photo fluoroscopy fifty years ago. 
However, in other places such as China (Sankaranarayanan, Black et al. 
1998)，USA (Ries LAG et al, 1997) and Europe (Berrino, Gatta et al. 
2001)，5-year survival rate is still around 20-25%. 
2 
1.2. Risk Factors of Gastric Cancer 
Occurrence and prognosis of gastric cancer can be attributed to multiple 
factors, such as dietary habits, Helicobacter pylori infection, health care 
system, and social-economic environment. 
Helicobacter pylori infection has been proven to be the most important 
risk factor. Regions with high gastric cancer incidences generally share 
high prevalence of Helicobacter pylori infection (Parsonnet 1995). The 
infection of Helicobacter pylori mainly happened during early childhood 
(Feldman RA, 2001) and the high infection prevalence is closely 
associated with poor living conditions, bad sanitation and disadvantaged 
social-economic environment. Occurrence of gastric cancer is also related 
to frequent consumption of salted, smoked or preserved food (Kono and 
Hirohata 1996; Ward and Lopez-Carrillo 1999; Kim, Chang et al. 2002; 
Lee, Kang et al. 2003). There are other reported risk factors, including 
obesity (Chow, Blot et al. 1998)，smoking (Koizumi, Tsubono et al. 2004)， 
radiation (Thompson, Mabuchi et al. 1994)，blood type A (AIRD I et al, 
1954), prior gastric surgery for benign conditions (Stalnikowicz and 
Benbassat 1990), and positive family history (Palli, Galli et al. 1994). 
3 
1.3. Treatment of Gastric Cancer 
1.3.1 Surgical treatment 
Surgery is the main method of treatment of gastric cancer. With the 
development of endoscopic techniques, surgical treatment enables an 
excellent prognosis for early gastric cancer with 5-year survival rate of 
more than 90%, although Ikeda reported that there was still 2.8% cancer 
recurrence and 5.0% second primary cancer occurrence within 10 years 
after cancer resected (Ikeda, Saku et al. 2005). However, the prognosis of 
advanced gastric cancers is still underdeveloped. Since the prognosis 
varies due to the stage of the tumor at the operation time and other 
histopathological features of the tumor, there is no accurate survival figure 
for advance gastric cancers. The overall figures of 30-40% 5-year survival 
for apparently curative resection are generally reported in Western centers 
(Degiuli, Sasako et al. 2004). The poor survival rate is mainly caused by 
the high recurrence rate due to frequent occurrences of loco-regional 
relapse, peritoneal dissemination, liver metastasis, distant metastasis even 
‘ after an RO resection. Therefore, certain effective adjuvant treatments are 
imperiously demanded. 
1.3.2 Chemotherapy 
Chemotherapy is a treatment by using chemicals that could kill cancer 
cells via impairing cell division or generation. Three clinical trials have 
4 
been performed aiming to investigate the efficacy of chemotherapy to 
metastatic gastric cancer (Murad, Santiago et al. 1993; Pyrhonen, Kuitunen 
et al. 1995; Glimelius, Ekstrom et al. 1997). The results show a clinically 
limited but statistically significant and constant efficacy of chemotherapy 
with median survival of 8-12 months, compared with 3-5 months for the 
case of supportive care. Theoretically, chemotherapy can be used as a 
preoperative, intraoperative or early postoperative adjuvant treatment. It 
may eradicate microscopic metastatic disease, prevent peritoneal 
dissemination as well as diminish surgical extent, and could even enable 
unresectable cancer potentially resectable. Though there are many 
advanced regimens consisting of more effective but less toxic 
chemotherapeutic agents such as docetaxel, oxaliplatin, irinotecan and 
capecitabine for chemotherapy, several new large, randomized phase III 
studies demonstrate that the best median survival with chemotherapy in 
phase III cases have not exceeded 12 months and toxicity remains 
inevitable (Hwang 2007). It would be of utmost interest to investigate 
other new combinations to prolong the survival time of patients with 
advanced gastric cancer and improve their quality of life. 
Most chemotherapeutic agents play roles in anti-growth of cancer cells by 
interfering with DNA synthesis or function. Based on their actions with 
different phases of cell cycle, chemotherapeutic agents can be categorized 
5 
into three types: cell cycle phase-specific agents, cell cycle phase-non-
specific agents and non-cell-cycle-specific agents. Cell cycle phase-
specific agents are effective during certain phases of cell cycle, including 
L-asparaginase for cells in G1 phase , anti-metabolites such as 5-
fluorouracil (5-FU) for cells in S phase, bleomycin for G2 cells and Vinca 
alkaloids such as Vincristine for M cells . Cell cycle phase-non-specific 
agents are effective during all phases of cell cycle, including alkylating 
ageuts such as cisplatin and anthracyclines such as Doxorubicin. Non-cell-
cycle-specific agents do not directly interfere with DNA, but could affect 
the overall phases of cells including those non dividing ones by 
modulating tumor behaviors. Antitumor antibiotics drugs, monoclonal 
antibodies and hormones belong to this categorized one. 
Among a variety of chemotherapeutic reagents, 5-fluorouracil (5-FU) is 
the most widely used anti-gastric cancer chemotherapy drug (Wilke, 
Preusser et al. 1990; Tsujinaka, Kido et al. 1992)and has been considered 
‘ as the core of classical chemotherapeutic regimes, mainly including CF 
(cisplatin plus infusional 5-FU) and ECF (cisplatin plus infusional 5-FU 
plus Epirubicin). The view as 5-FU for gastric cancers has been buttressed 
by a recent meta-analysis which indicates that 5-FU/cisplatin-based 
therapy produced a greater progresson-free survival and was suggested as 
the standard therapy for advanced gastric cancers (Wagner, Grothe et al. 
6 
2006). 5-FU belongs to the anti-metabolites of chemotherapeutic agents. 
As a pyrimidine analogue, 5-FU suppresses the DNA replication mainly 
by the formation of competitive 5 -fluoro-2-deoxy uridine-5 -
monophosphate (FdUMP), which could inhibit the activity of thymidylate 
synthase (TS), an essential enzyme for purimidine thymine 
synthesis(Spears, Gustavsson et al. 1984). 5-FU can also interrupt the 
RNA replication(Nord, Stolfi et al. 1992). In addition, 5-FU can arrest 
cancer cells at the Gl-S border and inhibit cells undergoing DNA 
synthesis(Pizzomo, Sun et al. 1995). Due to these effects, 5-FU essentially 
induces cell cycle arrest and apoptosis. 
1.3.3 Targeted therapy 
Targeted therapy is a newly developed treatment for different types of 
cancers by targeting key molecules in cancer cells based on the 
understanding of the molecular mechanisms underlying carcinogenesis. 
The strategies of targeted therapy mainly include suppressing tumor 
growth, inducing cancer cell apoptosis, enhancing sensitivity of cancer 
cells to chemotherapy, inhibiting angiogenesis and tumor cell spread, 
activating host immune response against tumor and protecting normal 
tissue during therapeutic process. Gastric cancer is developed from a 
multi-step progress (Deng 2000) involving multiple genetic and epigenetic 
alterations (Chen, Rocken et al. 2004). Inhibition of oncogenes such as C-
7 
myc, K-ras, c-erbB-2, EGFR has been widely studied in gastric cancer 
cells as well as in animal models and the results show in promising results 
in cancer growth inhibition and apoptosis (Hirao, Sawada et al. 1999; Song, 
Lee et al. 2000; Bi, Fan et al. 2001; Chen, Lin et al. 2001). The 
reactivation of tumor suppressor gene p53 was shown to be an alternative 
approach in gastric cancer treatment (Ohashi, Kanai et al. 1999). Herpes 
simplex virus (HSV) thymidine kinase (HSV-tk) / ganciclovir (GCV) 
system is widely studied as suicide gene / prodrug system in which 
prodrug GCV is converted into toxic phosphorylated GCV by means of 
non-mammalian enzyme HSV-tk which is overexpressed in neoplastic 
cells as a result of gene transfection. The suicide gene / prodrug system has 
a “ bystander effect" which could drastically enhance the capacity of 
killing tumors of HSV-tk / GCV system (Freeman, Abboud et al. 1993; 
Tanaka, Yamasaki et al. 2001). Inhibiting angiogenesis by blocking related 
growth factors such as the vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) is 
• reported useful in limiting cancer metastases (Tandle, Blazer et al. 2004). 
Gefitinib, an orally active epidermal growth factor receptor-tyrosine kinase 
inhibitor (EGFR inhibitor), has been studied in a Japan-Europe joint phase 
II study and shown a modest anti-cancer activity and good toleration for 
patients (Doi T et al, 2003). C0X2 inhibitor Aspirin has been reported to 
be associated with a reduced risk of noncardia gastric adenocarcinoma 
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(Wang, Huang et al. 2003). Although targeted therapy results in a great 
therapeutic efficacy in gastric cancer cell lines and animal models, the 
application in patients is still in its infancy due to complicated mechanisms 
of action, pharmacokinetica, toxicities as well as molecular 
characterizations and pathogenesis of different gastric cancers. Therefore, 
it would still be highly promising if clinicians could make an 
individualized treatment for cancer patients. 
1.4. Phenotypes of cell death: apoptosis, oncosis and autophagy 
1.4.1. Cell death 
Cell population processes three fundamental steps: cell division, cell 
growth and cell death. As living things, all types of cells in humans must 
eventually die as the results of regulations in inflammation, immune 
responses or tissue remodeling (Savill and Fadok 2000). Based on the 
biochemical and morphologic traits of dying cells, cell death are 
categorized into three phenotypes: apoptosis, oncosis and autophagy 
(Yasuhara, Asai et al. 2007). 
1.4.2 Apoptosis 
Apoptosis, also known as type-1 programmed cell death, is characterized 
by cellular shrinkage, chromatin condensation and margination, intact 
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plasma membrane and cellular organelles, as well as fragmental nuclei and 
apoptotic bodies. It is considered as a regulated cell death which plays an 
important role in the regulations of development, morphogenesis, and 
homeostasis in normal tissue. It is estimated that around 10 billion cells are 
dying by apoptosis each day in order to maintain homeostasis in an adult 
human body (Renehan, Booth et al. 2001). Apoptosis is critically 
important to rid the body of pathogen-invaded cells or DNA damaged cells 
and eliminate activated or auto-aggressive immune cells(Osbome 1996; 
Greenhalgh 1998).Apoptosis also plays a key role in cell proliferation in 
various tumors and also associated with turnover of normal cells into 
malignantly proliferated tumor cells. Failure to activate apoptosis after 
DNA injury is a known route to carcinogenesis (Lowe, Jacks et al. 1994; 
Griffiths, Clarke et al. 1997). Several genes regulating apoptosis in human 
have been identified as the counterparts of those in Caenorhabditis elegans: 
bcl-2, Apaf-1 and caspase-3 in human are respectively counterparts of 
CED-9, CED-4 and CED-3 in Caenorhabditis elegans (Vaux, Weissman et 
‘ al. 1992; Yuan and Horvitz 1992; Yuan, Shaham et al. 1993)，from which 
could be referred that the basic mechanism of apoptosis is evolutionarily 
conserved (Vaux 1997), Though detailed mechanism is still under 
investigation, various intracellular signals leading to apoptosis have been 
identified, including three pathways: Fas and tumor necrosis factor-a 
receptors-dependent pathway initiated by extrinsic signaling, 
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mitochondria-dependent pathway and endoplasmic reticulum(ER)-
dependent pathway initiated by intrinsic signaling. Most apoptotic 
processes require activation of caspases, a variety of proteases which could 
activate one another and result in a cascade of enzymatic chain reaction 
leading to cell apoptosis. Fas and TNR-a receptor ligands bind with 
activation of caspase-8, apoptosis in mitochondria-dependent pathway is 
associated with activation of caspase-9 and ER-dependent apoptosis 
involves activation of caspase-12 (Nakagawa, Zhu et al. 2000). 
1.4.3. Oncosis 
Oncosis is a form of cell death characterized by cell swelling, ruptured 
plasma membrane, disintegrated cytoplasm/organelles, and unspecific 
DNA breakage. It usually occurs during critical illness such as ischemia, 
bums, sepsis, trauma, AIDS, tumor-related cachexia and is thought of as 
an unregulated type of cell death. Its heterogenic nature makes the 
underlying mechanism still unclear. However, Calpain has been identified 
to be closely associated with oncosis (Liu, Van Vleet et al. 2004). Under 
ischemic stress or in other tough living conditions, calcium in cells flows 
into the cytoplasm from organelles due to less ATP for energy supplement. 
Increased cytoplasmic concentration of free calcium ion activates calpain 




Autophagy, also known as type-2 programmed cell death, is marked by 
autophagosomes in cytoplasm and engulfment of cellular components. 
Autophagosomes are large vesicles with double bounded membranes, 
sequestering cytosol and organelles such as mitochondria. 
Atuophagosomes will finally merge with lysosomes containing acid 
hydrolase and degrade the cellular constituents for recycling. Hence it is 
generally thought of as a regulated self-cannibalism for cells in order to 
survive in starvation and during development (Klionsky 2004). Triggering 
an appropriate signal to induce or suppress autophagy is important in the 
cellular component degradation and metabolic processes for cells. Unlike 
apoptosis, autophagy is a caspase-independent process. A subset of 
molecules autophagy-related genes (Atg) participate the signal 
transduction of autophagy, such as Atg5, Atg 12, Atg 16 and LC3/Atg8 
(Yasuhara, Asai et al. 2007). 
1.4.5. p53 
p53, tumor suppressor gene, locates at 17pl3 containing 11 exons and 
encodes a 53 kD phosphoprotein which is a transcription factor for genes 
that induce cell cycle arrest or apoptosis (Levine 1997). p53 is also 
associated with genomic stabilization and angiogenesis inhibition 
(Dameron, Volpert et al. 1994) , partly because p53 can be activated by 
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variety of DNA damages, including double-strand breaks in DNA 
produced by y-irradiation and the presence of DNA repair intermediates 
after ultraviolet irradiation or chemical damage to DNA and the activation 
of p53 as a transcription factor causes a G1 arrest or triggers apoptosis. 
Loss of p53 function could result in defective DNA replication and 
malignant transformation (Kastan, Onyekwere et al. 1991), genetic 
instability as well as high survival of mutant cells (Levine 1997). 
Moreover, p53 is associated with the tumorgenesis, for its mutations are 
found in 50-55% of all human cancers(Hollstein, Rice et al. 1994) 
Mutations more commonly happened in metastatic than in primary gastric 
carcinomas and the percentage of mutations in gastric cancer cell lines in 
general is higher than that in primary gastric cancer (Kim, Takahashi et al. 
1991; Yamada, Yoshida et al. 1991; Matozaki, Sakamoto et al. 1992). 
However, the impact of p53 mutation on gastric cancers is still unclear. 
There is a suggestion offered by two interesting studies that tumors with 
intermediate levels of p53 expression have the lowest risk of metastasis, 
while tumors that are either negative or strongly positive are more likely to 
metastasize (Setala, Kosma et al. 1998; Shiao, Palli et al. 2000). It is so far 
clear that p53-mediated apoptosis is an important part of the tumor 
suppressor phenotype and subsequent selection for mutant p53 genes in 
cancers. Cells with wild-type p53 often respond well to chemotherapeutic 
intervention, such as childhood acute lymphoblastic leukemias (Lowe, 
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Ruley et al. 1993) and testicular teratocarcinomas (Lutzker and Levine 
1996), while other tumors frequently bearing mutant p53 (melanoma, lung 
cancers, colorectal tumors and bladder and prostate cancers) often respond 
poorly. On the other side, the good correlation between p53 status and 
treatment response or prognosis is not always the case due to the large 
number of genetic changes that cancer cells usually suffers and the 
complicated cellular environment during treatments. Therefore, further 
investigation is still in order to make accurate predictions. 
1.5. Heme oxygenase-1 
1.5.1. General introduction of Heme oxygenase 
Heme oxygenase (HO) is the rate-limiting enzyme in the degradation of 
heme by generating ferrous free iron, carbon monoxide and biliverdin, 
which is subsequently reduced to bilirubin by biliverdin reductase. 
Heme + 3 Ahb + 3 O2 一 biliverdin + Fe^* + CO + 3A + 3 H2O 
Heme oxygenase is ubiquitously present in almost all types of organs and 
tissues, especially in liver, spleen, testis, kidneys, brain, and heart. There 
are three isoforms of HO: HO-1, HO-2 and HO-3, which are the products 
of three different genes (Maines 1988). HO-2 is a constitutive isoform, 
highly present in the brain, testis, or endothelial cells, while HO-3 is 
similarly present to HO-2 but with much lower catalytic activity. Among 
three isoforms of HO, HO-1 is the most widely investigated one because 
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of not only its ubiquitous distribution, but also its inducible traits by many 
stimuli such as substrate heme, heat shock, oxidative stress, hypoxia, 
hyperoxia, ultraviolet, inflammatory cytokines, prostaglandins, ethanol, 
heavy metals, etc. A wide variety of physiological and pathological 
processes, including chronic obstructive lung disease, hypoxic/ischemic 
injury, transplant rejection, cancer, etc, involve the essential participation 
of HO-1. It is generally believed that HO-1 in tissues plays the roles of 
anti-oxidative stress, anti-inflammation, and pro-angiogenesis. 
Furthermore, HO-1 is also associated with the regulations of cell 
proliferation. 
1.5.2. Anti-oxidant function of HO-1 
HO-1 deficiency mice are suffered from sustained oxidative stress, severe 
lipid peroxidation and is abnormally sensitive to heme- or H2O2- mediated 
cytotoxicity (Poss and Tonegawa 1997). The antioxidative function of HO-
1 is mainly due to the removal of heme, a potent prooxidant agent and the 
generation of biliverdin, a scavenger of peroxyl radical, and the 
sequestration of iron by ferritin. 
1.5.3. Anti-inflammation function of HO-1 
The anti-inflammation ability in vivo is highly associated with the 
signaling action of CO, which has been identified as an efficient anti-
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inflammatory mediator by decreasing the generation of inducible nitric 
oxide synthase (iNOS)-derived NO and other inflammatory related factors 
such as TNF, IL-6 (Otterbein, Bach et al. 2000; Sawle, Foresti et al. 2005) 
while increasing the production of anti-inflammatory cytokine IL-10 in 
macrophages(Sawle, Foresti et al. 2005). The other productions of HO-1 
such as biliverdin/bilirubin and Fe^ "^  chelation also participate in the anti-
inflammatory response via regulation of various adhesion molecules such 
as E-selectin, intracellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1) by inhibiting nuclear factor-kB (NF-kB) 
activation(Hayashi, Takamiya et al. 1999). 
1.5.4. Pro-angiogenesis role of HO-1 
Angiogenesis is the formation of new blood vessels from preexisting ones. 
It has been proven to play a critical role in tumor growth and metastasis, 
which are the major causes of poor clinical prognosis for cancer patients. 
The pro-angiogenesis role of HO-1 has been convinced in human gliomas 
(Nishie, Ono et al. 1999)，human vertical growth melanomas (Torisu-
Itakura, Fume et al. 2000)，pancreatic cancers (Sunamura, Duda et al. 
2003), lung carcinomas(Hirai, Sasahira et al. 2007)，and murine melanoma 
(Was, Cichon et al. 2006). Similar effects of over-expression of HO-1 
were demonstrated that up-regulated HO-1 led to more formation of 
capillary-like tubular structures and more cell migration. The underlying 
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mechanism is still not clear. However, to our best knowledge, the pro-
angiogenesis role of HO-1 is partly due to the increased expression of 
vascular endothelial growth factor (VEGF) which could be mediated by 
CO (Dulak, Jozkowicz et al. 2002). Some research indicates that the pro-
angiogenesis role of HO-1 played is also related to up-regulation of EGF, 
thymosin- p (Tp4), hyaluronidase-1 (HYAL-1) and malignant T cell-
amplified sequence-1 in melanoma cell line (MCT-1) (Was, Cichon et al. 
2006). 
1.5.5. HO-1 and cell proliferation 
The effect of HO-1 on cell proliferation is complicated and diversified 
depending on cell and cancer types. Mostly, HO-1 has been demonstrated 
to be able to stimulate the proliferation of numerous types of cells such as 
epidermal keratinocytes (Clark, Green et al. 1997), epidermis 
(Hanselmann, Mauch et al. 2001), vascular endothelium (Deramaudt, 
Braunstein et al. 1998) and HO-1 expression is significantly upregulated in 
various tumor cells, including oligodendroglioma(Deininger, Meyermann 
et al. 2000), hepatoma (Doi, Akaike et al. 1999), renal cell 
carcinoma(Goodman, Choudhury et al. 1997), melanoma (Torisu-Itakura, 
Fume et al. 2000), squamous carcinoma cells (Tsuji, Yanagawa et al. 
1999), prostate cancer (Maines and Abrahamsson 1996), and gastric 
cancer (Lo, Lin et al. 2007). Accordingly, it has been demonstrated that 
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inhibition of HO-1 could result in the decreased growth of above tumors. 
Such pro-proliferation function of HO-1 is considered due to the 
decreased expression of two negative regulators of cell cycle, p21 and B-
cell translocation gene-2 (BTG2) (Was, Cichon et al. 2006). However, 
there are few occasions that HO-1 plays a role of negative growth 
regulator in cells such as epithelium (Aizawa, Ishizaka et al. 2001)， 
astroglia (Song, Su et al. 2006), T lymphocytes (Song, Mahidhara et al. 
2004), smooth muscle cells (Ollinger, Bilban et al. 2005) and breast cancer 
cells (Hill, Pereira et al. 2005). Mechanisms involved still require 
elucidation, but it is justified that anti-proliferative activity of HO-1 is 
mediated by its production of CO via activation of the p38 mitogen-
activated protein kinase (p38-MAPK) and sGC/cGMP signaling pathway 
which results in elevated expression of caveolin-1 and p21, 
downregulating cyclin A and finally arresting cell growth (Kim, Wang et 
al. 2005). 
1.5.6 HO-1 as a therapeutic target for tumors 
HO-1 is generally regarded as a cytoprotective enzyme due to its anti-
oxidative and anti-inflammatory function. HO-1 deficient (HO-l'^") mice 
and humans exhibit severe growth retardation (Poss and Tonegawa 1997; 
Yachie, Niida et al. 1999)，while the systemic administration of a 
retrovirus containing the human HO-1 gene to young rats generates a 
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distinctive increase in body weight and size comparing with control group 
(Sabaawy, Zhang et al. 2001). However, cytoprotective function of HO-1 
in tumors seems to have a "bad" effect on human. Additionally, the pro-
angiogenesis trait of HO-1 facilitates not only growth but also the 
infiltration and spread of tumor cells. The majority of tumors highly 
express HO-1 (Maines and Abrahamsson 1996; Goodman, Choudhury et 
al. 1997; Doi, Akaike et al. 1999; Tsuji, Yanagawa et al. 1999; Deininger, 
Meyermann et al. 2000; Torisu-Itakura, Fume et al. 2000; Lo, Lin et al. 
2007). More interestingly, HO-1 is strongly induced in tumors which are 
treated by chemotherapeutics, radiotherapy or photodynamic therapy 
(Maines and Abrahamsson 1996; Henry, Bretaudeau et al. 1998). It can be 
postulated that the induction of HO-1 enhances the resistance of tumors to 
anti-cancer treatments and thus HO-1 may be a potential target in anti-
cancer therapy by inhibiting expression or activation of HO-1 to enhance 
the sensitivity of cancers to clinical therapies. 
Mostly common used inhibitors of HO-1 are metalloporphyrins 
(Thompson, Mabuchi et al.), which could interact with the heme binding 
site of heme oxygenase protein. 
Zinc protoporphyrin-IX (ZnPP)(Maines 1981), zinc mesoporphyrin 
(ZnMPIX), tin protoporphyrin-lX (SnPPIX) (Berglund, Angelin et al. 
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1990)，and tin mesoporphyrin-IX (SnMPIX) (Galbraith, Drummond et al. 
1992) have been subscribed as HO-1 inhibitors in vitro and in vivo animal 
studies. Nevertheless, ZnPP is the most commonly used one due to the 
following characteristics: 1) It is a normal metabolite formed during heme 
biosynthesis, so it would not affect heme biosynthetic enzymes or cellular 
actions related to hemoproteins and would be well tolerated if exogenous 
ZnPP was administrated in vivo (Labbe, Vreman et al. 1999). 2) It 
possesses the strongest potency of inhibiting HO-1 (Yang, Nguyen et al. 
2001). 3) Intact ZnPP is not photosensitivity and do not cause 
photohaemolysis (Labbe 1977). 
ZnPP, as an HO-1 antagonist, can either inhibit HO-1 activity (Maines 
1981) or down-regulate HO-1 expression (Ana J. Coito, 2002; Katori, in 
press) or both. As early as 1981, MAHIN D. MAINES reported that the 
mechanism of HO-1 inhibition by ZnPP appears to be competitive in 
nature, as ZnPP interacts with the heme binding site of heme oxygenase 
protein . However, the down-regulation of HO-1 expression may be due to 
the lower efficiency of protein translation as Steve Braunstein (Steve 
Braunstein, 1999) reported that ZnPP induces HO-1 mRNA levels in many 
• human cells and tissues, indicating that the process from mRNA to protein 
is inhibited by ZnPP. 
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1.6. Objectives of study 
Considering high incident rate yet relatively low survival rate of gastric 
cancer in China, we try to find a way to improve the treatment efficiency 
for gastric cancer. With the development of targeted therapy for cancers, 
more and more cancer related molecules, genes and proteins are being 
investigated. It is known that HO-1 expression is associated with gastric 
cancer (Lo, Lin et al. 2007) and the pharmacologic upregulation of HO-1 
expression significantly improves survival of gastric cancer cells (Liu, 
Chen et al. 2004). Based on current research on HO-1, we conclude that 
HO-1 promotes growth of gastric cancer, facilitates metastasis and 
enhances the resistance to anti-cancer treatments. The mechanism 
responsible is mainly due to its three basic functions, namely, anti-
oxidation, anti-inflammation, and pro-angiogenesis. We hypothesize that 
gastric cancer cells will be more sensitive to chemotherapeutic agents if 
HO-1 is inhibited. 
In our experiments, we would like to investigate: 
(1) Whether the inhibition of HO-1 could enhance the sensitivity of gastric 
cancer cells to anti-cancer chemotherapy. 
(2) What mechanisms underlying the roles of HO-1 in chemotherapy of 
gastric cancer are. 
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Chapter Two: Methods and materials 
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2.1. Gastric cancer cell lines 
Two gastric cancer cell lines MKN28 with mutant p53 (JCRB0253) and 
MKN45 with wild p53 (JCRB0254) were used in the project. Cells were 
cultured in RPMI 1640 containing 10% fetal bovine serum (FBS) 
(HyClone, Logan, UT), 100 U/ml penicillin, 100 |xg/ml streptomycin and 
incubated at 37 T with 5% CO2 /95% air. 
2.2. Cell proliferation detection 
2.2.1. MTT (3-(4,5-Din[iethylthiazol-2-yl)-2,5-cliphenyltetrazolium 
bromide) assay 
2.2.1.1. Introduction of MTT assay 
The MTT assay is a commonly used method to detect cell viability. The 
basic principle for this method is that yellow MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) can be reduced 
by mitochondrial reductase to purple formazan in the mitochondria of 
living cells, so the amount of purple formazan produced is related with the 
amount of living cells. In our lab, the stock concentration of MTT (Sigma-
Aldrich, St. Louis, MO) was 5mg/ml and 0.5mg/ml was used as the 
working concentration 
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2.2.1.2. Processes of MTT assay 
The cells were cultured in 100mm dishes filled with complete RPMI at 37 
°C, 5% CO2 until 80% confluence. They were detached by trypsin and 
then resuspended in RPMI with a concentration of 5xlO'^/ml and finally 
seeded into a 96-well plate in a density of 5000 cells per well. Cells were 
required to grow for overnight in order to be well attached the plate before 
drug treatments. Targeted drugs were then added with certain 
concentration in triplicate and blank controls were also made for each 
treatment of each cell line (Figure 2.1). The plates were incubated in 37 °C 
for several hours (for example, 12h, 24h, 48h, 72h) depending on cell 
conditions after different drug treatments and then were added to each well 
with 10 |il of 5mg/ml MTT solution. They were placed back in the 
incubator for MTT conversion. After 4 hours, the medium was discarded 
and 200 of DMSO (Sigma-Aldrich, St. Louis, MO) was added into each 
well to resuspend the formazan dye. The plates were then kept in dark for 
30 minutes. Absorbance was measured by a spectrophotometer at 560 nm 
with a background absorbance at 670 nm. 
2.2.1.3. Cell proliferation and cytotoxicity of drugs 
Cell proliferation of drug-treated cells was compared with non-treated 
control cells. The following formula was used for calculation: 
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Cell proliferation rate (%)= 
(Absorbance of drug-treated cells /Absorbance of non-treated control cells) 
X 100% 
Cytotoxicity of drugs (death rate %)= 
(1- Absorbance of drug-treated cells/ absorbance of non-treated control 
cells) X 100% 
2.2.2. Detection of apoptosis by TUNEL assay 
2.2.2.1. TUNEL (Terminal uridine deoxynucleotidyl transferase dUTP 
nick end labeling) 
TUNEL, as the most common used method for cell apoptosis assay，is 
based on the principle that DNA strand in apoptotic cells breaks as a result 
of endonuclease activation and the 3'-hydroxy 1 ends of DNA fragments 
could be labeled in situ in individual fixed cell with bioti/fluorescein -
dUTP mediated by terminal deoxynucleotidyl transferase (TdT) (Gavrieli, 
Sherman et al. 1992). The labeled cleavage sites in apoptotic cells could be 
detected directly or indirectly by Flow Cytometry (FCM). Non-apoptotic 
cells do not incorporate significant amounts of the F-dUTP owing to the 
lack of exposed 3'-hydroxy 1 DNA ends. 
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2.2.2.2 Sample preparation 
Cell culture 
Control- and drug-treated cells were seeded in 6-well plates (Becton 
Dickson Labware, Franklin Lakes, NJ) in a density of 3 X 10^  cells per 
well and grew overnight before drug treatments. Cells were treated with 
drugs on the second day and then incubated at 37 °C, 5% CO2 for several 
hours depending on experimental need before collection. 
Cell fixation 
Medium in each well was collected in a 10 ml centrifuge tube. Cells were 
washed with 1 ml of PBS which was also collected into the same tube. 
Cells per well were then detached by 300 |il trypsin and collected to the 
respective tube. Each tube was centrifuged at 2000 rpm for 5 minutes and 
then supernatant was discarded. Once again each tube was washed with 4 
ml of PBS and centrifuged at 2000 rpm for 5 minutes. Supernatant was 
decanted and cells were resuspended in 1% (w/v) paraformaldehyde in 
PBS, pH 7.4 at a concentration of 1 X 1ce l l s /ml . Then cells were placed 
on ice for 30 minutes. After that, cells were centrifuged at 2000 rpm for 5 
minutes and supernatant was discarded. Cell pellets were washed with 4 
ml PBS and centrifuged at 2000 rpm for 5 minutes. Finally cell pellets 
were resuspended with 0.5 ml PBS and was added with 4.5 ml 75% ice-
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cold ethanol (v/v) slowly with constant vortex. Cells should be fixed at -
20�C at least overnight before further analysis. 
Cell staining 
APO-DIRECT™ Flow Cytometry Kit for Apoptosis (Chemicon, 
Temecula, CA) was employed. Cells that had been fixed were centrifuged 
at 2000 rpm for 5 minutes and supernatant was removed. Then cell pellets 
were resuspended with 4 ml of wash buffer and were centrifuged again at 
2000 rpm for 5 minutes. Supernatant was removed again and cells were 
washed with wash buffer for the second time. After that, cell pellets were 
resuspended in 50 of staining solution which was a mixture with the 
- following components: 
Table 2.1. Staining solution of TUNEL assay 
Staining solution component Volume (|il )(1 assay) 
TdT Reaction Buffer 10 
TdT Enzyme 0.75 
Fluorescein-dUTP 8 
Distilled water 32.25 
Cells were stained for 60 minutes at 37 in a temperature controlled bath 
and were shaken every 15 minutes. After staining, cells were added with 
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1ml Rinse Buffer and centrifuged at 2000 rpm for 5 minutes. Supernatant 
was removed and cells were washed with 1 ml Rinse Buffer for the second 
time. Finally cells were ready for Flow cytometry analysis. 
Flow cytometry analysis 
Fluorescein-dUTP labeled DNA breaks in apoptotic cells can be detected 
by flow cytometry. Apoptosis was measured according to the protocol 
provided by the kit and the results were presented as % fold of control 
condition. 
2.3. Detection of cell cycle by flow cytometry 
2.3.1. Cell cycle 
The cell cycle consists of four distinct phases: G1 phase, S phase, G2 
phase and M phase. G1 phase is from the end of the previous M phase to 
the beginning of DNA synthesis and marked by synthesis of enzymes that 
required in DNA replication. S phase is for DNA synthesis. Through after 
S phase, chromosomes of cells are replicated. G2 phase is from the ending 
of S phase until the beginning of M phase and mainly for protein synthesis. 
Cells then enter the M phase, on which chromosomes and cytoplasm are 
divided into two daughter cells. Besides the four phases of cell cycle, there 
is a state of quiescence of cells called GO phase, on which phase cells are 
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not undergoing proliferation but could be induced to enter the cell cycle 
from G1 phase. ( Fig 2.1) 
2.3.2 Sample preparation 
Cell culture 
Cells were cultured with the same method as the above mentioned (see 
2.2.2.2 cell culture) 
Cell fixation 
Medium in each well was collected in a 10 ml centrifuge tube. Cells were 
washed with 1 ml of PBS which was also collected into the same tube. 
Cells per well were then detached by 300 m> trypsin and collected to the 
respective tube. Each tube was centrifuged at 2000 rpm for 5 minutes and 
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then supernatant was discarded. Once again each tube was washed with 4 
ml of PBS and centrifuged at 2000 rpm for 5 minutes. Supernatant was 
removed and cell pellets were resuspended in 0.5ml PBS, pH 7.4. After 
that, cell suspension was added with 4.5 ml 75% ice-cold ethanol (v/v) 
slowly with constant vortex. Cells should be fixed at -20 °C at least 
overnight before further analysis. 
Cell staining 
Fixed cells were centrifuged at 2000 rpm for 5 minutes and supernatant 
was removed. Then cells were washed with 5 ml PBS for two times. After 
that, cell pellets were resuspended in 0.5 ml of propidium iodide 
(PiyRNase A solution and incubated in dark for 30 minutes at room 
temperature. Then cells were kept on ice for flow cytometry analysis. 
2.3.3. Flow cytometry analysis 
Cell cycle analysis by flow cytometry is based on the characteristic DNA 
contents of cells in different growing phases. In the theory, cells in the 
GO/Gl phases will take up the same amount of DNA-binding 
fluorochromes and fluoresce in a single channel because they have the 
same amount and morphology of DNA. Cells in the G2/M phases will take 
up the double amount of fluorochromes because they have doubled their 
chromosomes after completing the S phase. Cells in S phase take up 
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fluorochromes less than those in G2/M phases but more than those in 
GO/Gl phases and fluoresce in various channels because cells in this phase 
are undergoing DNA replications and it is impossible for all the cells keep 
in the same pace of progress. Therefore, there are two peaks showed by 
Flow cytometry respectively inferring two groups of DNA amounts of 
cells in different cell cycles. Using propidium iodide as a DNA binding 
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Fig.2.2. Demonstration of cell cycle analyzed by FCM 
2.4. Detection of mitochondrial membrane potential(A^m ) 
2.4.1. Sample preparation 
Cell culture 
Cells were cultured with the same method as the above mentioned (see 
2.2.2.2 cell culture) 
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Cell staining 
Cells were added with molecular probe lOuM DiOC6 (3,3'-
dihexyloxacarbocyanine iodide) for 2 hours before collection and kept in 
37 °C incubator to load the dye. 
Cell collection 
Medium in each well was collected in a 10 ml centrifuge tube. Cells were 
washed with 1 ml of PBS which was also collected into the same tube. 
Cells per well were then detached by 300 pi trypsin and collected to the 
respective tube. Each tube was centrifuged at 2000 rpm for 5 minutes and 
then supernatant was discarded. After that each tube was washed with 4 ml 
of PBS and centrifuged at 2000 rpm for 5 minutes for two times. 
Supernatant was removed and cell pellets were resuspended in 0.5ml PBS, 
pH 7.4. Fresh cell suspension should be kept on ice for further analysis. 
2.4.2. Mitochondrial membrane potential(A屯m ) analysis by Flow 
cytometry 
Cells undergoing early apoptosis show a loss of mitochondrial membrane 
potential (A^^) (Vayssiere, Petit et al. 1994; Zoratti and Szabo 1995). 
A少;„ changes can be assessed by mitochondrial staining with DiOQ and 
detected by flow cytometry using a 530 nm filter. 
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2.5. Detection of proteins investigated in the project 
2.5.1. Antibodies 
Antibodies used and their dilutions were listed below: 
Table 2.2. List of antibodies used in apoptotic assay 
Primary Dilution Secondary Dilution 
antibodies antibodies 
HO-l(Hsp 32) 1:2000 Goat anti- 1:2000 
mouse IgG 
HRP 
mouse (Santa Cruz 
monoclonal Biotechnology, 
antibody IgGl Inc., Santa 




Caspase-3 (sc- 1:2000 Goat anti- 1:2000 
7148) mouse IgG 
HRP 
rabbit (Santa Cruz 











mouse (Santa Cruz 
monoclonal Biotechnology, 





AIF(sc-5586) 1:1000 Goat anti- 1;2000 
rabbit IgGi 
HRP 
rabbit (Santa Cruz 







Actin (C-11) 1:2000 Bovine anti- 1:2000 
goat IgG HRP 
goat (Santa Cruz 








2.5.2 Sample Preparation 
2.5.2.1 Cell culture 
Control- and drug-treated cells were seeded in 100 mm dishes and grew 
until 70% confluence before drug treatments. Cells were then treated with 
drugs at various concentrations for different times depending on 
experimental need before collection. 
2.5.2.2. Protein extraction 
Total protein extraction: 
Medium in each dish was collected into 15 ml tubes. Cells were scraped 
and collected into respective tube. Tubes containing cells were then 
centrifuged at 2000 rpm for 5 minutes. Suspension was discarded and cell 
pellets were resuspended twice with PBS followed by centrifuging at 2000 
rpm for 5 minutes. After washing steps, cell pellet were resuspended with 
the mixture of 500 |al of ice-cold RIPA buffer (IX PBS, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS) and 10 )il of protease inhibitors cocktail. 
Cells were homogenized by passing through 21G needle for 20 times and 
then incubated on ice for 45 minutes. Samples were centrifuged at 1 OOOOg 
for 10 minutes at 4 °C . Supernatant obtained after centrifuging was the 
total protein in cells. Proteins were stored at -20 °C for future use. 
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Cytosolic, nuclear and mitochondrial protein extraction 
As the total protein extraction, medium in each dish was collected into 15 
ml tubes. Cells were scraped and collected into respective tube and then 
centrifuged at 2000 rpm for 5 minutes. Cell pellets obtained were 
resuspended twice with PBS followed by centrifuging at 2000 rpm for 5 
minutes. Then cells were resuspended in 100 \i\ Buffer A (20mM HEPES, 
pH 7.5; 1.5mM MgCb； lOmM KCl; ImM Sodium EDTA; ImM Sodium 
EGTA; ImM DTT; O.lmM Phenylmethylsulfonyl fluoride; lOOmM 
NasVOs； protease inhibitor cocktail). Cell suspension was homogenized 
with a 200 i^l pipette tip for 60 times and then centrifuged at 750xg for 10 
minutes at 4°C. Cell pellets were resuspended in 500 ice cold NE Buffer 
A (lOmM HEPES, pH 7.9; 1.5mM MgCb； lOmM KCl; 0.5M DTT; 0.5mM 
Phenylmethylsulfonyl fluoride; lOOmM NasVOs； protease inhibitor 
cocktail). Supernatant obtained after centrifugation of 750xg was collected 
into another 1.5ml tube and centrifuged at 10,000xg for 15 minutes at 4°C. 
The pellets obtained were mitochondrial proteins and finally resuspended 
in Buffer A. The supematants were then centrifuged at 100,000xg for one 
hour at 4°C and the supematants obtained were cytosolic extract. The cell 
suspensions in NE Buffer A were kept on ice for 15 minutes and then 
added with 30 |il 10% Nondet NP-40. The samples were vortexed for 10 
seconds and spinned at 10,000 rpm for 30 seconds at 4°C. Supematants 
were removed and pellets were resuspended in 50 NE Buffer B (5mM 
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HEPES, pH 7.9; 1.5mM MgCb； 0.2mM EDTA; 26% (v/v) glycerol; lOmM 
DTT; 0.5mM Phenylmethylsulfonyl fluoride; lOOmM NasVO�； protease 
inhibitor cocktail). The suspensions were homogenized vigorously for 15 
min at 4°C and then centrifuged at 13,000 rpm for 10 minutes at 4°C. The 
supematants obtained were nuclear extract. Proteins were stored at -20 
for future use. 
2.5.2.3. Protein assay 
Measurement of total protein concentration 
Protein concentration was determined by using Bio-Rad DC (detergent 
compatibility) Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA). 
Reagent A’ was a mixture of reagent S and reagent A by a proportion 20 
|il of reagent S to 1 ml of reagent A. Four protein standards were prepared 
by serial dilutions of 1.44 mg/ml bovine serum albumin (BSA) standard to 
the following concentrations: 1.44 mg/ml, 0.72 mg/ml, 0.36 mg/ml, 0.18 
mg/ml. Samples were diluted by 1:5 with RIPA. Five microliters of 
standards or samples were added to a microplate in triplicate and then 25 
jil reagent A’ per well was also added. After that, 200 )il of reagent B per 
well was added and mixed by shaking gently. Plate was incubated at room 
temperature for no less than 15 minutes. Protein concentrations in wells 
were analyzed by a microplate reader with absorbance at 750 nm. 
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Measurement of mitochondrial protein and nuclear protein concentrations 
Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA) was 
employed. Reagent for assay was prepared by diluting one part of Dye 
Reagent Concentrate with four parts of distilled water. Eight protein 
standards were prepared by serial dilutions of 1.44 mg/ml bovine serum 
albumin (BSA) standard to the following concentrations: 1000 |ig/ml, 500 
昭/ml, 250 ^ig/ml, 300 ^ig/ml, 200 昭/ml，150 昭/ml, 100 ng/ml, 50 [ig/ml 
Mitochondrial proteins were diluted 3 times with extracting Buffer A 
(mentioned in 2.5.2.2. ) and nuclear proteins were diluted 5 times with 
extracting Nuclear Buffer B (mentioned in 2.5.2.2. ) so as to a 
concentration within the linear range of the standards. Ten microliters of 
standards or samples were added to a well of 96-well plate in duplicate and 
followed by adding 200|xl of dye reagent. Solutions were mixed with 
gently shaking and incubated at room temperature for no less than 5 
minutes and no more than one hour. Protein concentrations in wells were 
analyzed by a microplate reader with absorbance at 595 nm. 
2.5.2.4. Final loading protein 
30 |ag of total protein in each sample were prepared for western blotting 
while 15 |j,g of mitochondrial protein and nuclear protein were required. 
5X SDS loading buffer (60mM 4X Tris-Cl/SDS, 25% glycerol, 2% SDS, 
p-ME, 0.1% bromophenol blue) was added and mixed with each sample. 
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Samples with loading dye were then boiled at 100 °C for 5 minutes to be 
denatured and ready for use. 
2.5.3. Western blotting 
Electrophoresis in Sodium dodecyl sulfate- polyacrylamide gel (SDS-
PAGE) 
Mini-PROTEAN 3 Electrophoresis Module (Bio-Rad Laboratories, Inc., 
Hercules, CA) was employed. Depending on the size of detective proteins , 
14% resolving polyacrylamide gel (7 ml of 40% acrylamide/Bis, 5 ml of 
4X Tris-Cl/SDS, pH 8.8, 8 ml of H2O，180 ul 10% APS, 12 ul TEMED) or 
12% resolving polyacrylamide gel (6 ml of 40% acrylamide/Bis, 5 ml of 
4X Tris-Cl/SDS, pH 8.8, 9 ml of H2O，180 ul 10% APS, 12 ul TEMED) or 
10% resolving polyacrylamide gel (5 ml of 40% acrylamide/Bis, 5 ml of 
4X Tris-Cl/SDS, pH 8.8，10 ml of H2O’ 180 ul 10% APS, 12 ul TEMED) 
were applied. 5% Stacking gel (0.625 ml of 40% acrylamide/Bis, 1.25 ml 
of 4X Tris-Cl/SDS, pH 6.8, 3 ml of H2O, 10% APS, TEMED) was set 
above the resolving gel. Samples were loaded into each lane of settled gel 
and ten microliters of Full-Range Rainbow Molecular Weight marker 
(Amersham Biosciences, Buckinghamshire, UK) were also loaded as a 
protein size indicator. Proteins were resolved with 120 V for 1.5 hours 
after 100 V for running in the stacking gel. 
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Transferring of proteins to the nitrocellulose membrane 
After electrophoresis, the gel was equilibrated in transfer buffer (25 mM 
Tris, 192 mM glycine, 20% methanol, pH8.3) for few minutes. The 
Hybond membrane (Amersham Biosciences, Buckinghamshire, UK) was 
presoaked for 20 minutes before use while filter papers and sponges were 
also presoaked in transfer buffer. After that, the gel and the membrane 
were placed like a sandwich as the following sequence: sponge, filter 
paper, gel, membrane, filter paper, sponge. During the "sandwich" making, 
air bubbles were avoided, especially between the gel and the membrane. 
The set was put in a tank containing ice-cold transfer buffer with an ice 
block and buffer was stirred during transferring to avoid locally 
overheating. Finally, protein was transferred from the gel to the membrane 
under lOOV for one hour. 
Blocking of membranes 
Tris-buffered saline (200 mM Tris-Cl, 137 mM NaCl, pH 7.5) with 0.1% 
Tween 20 (TBST) was used after protein transfer. Membranes were 
equilibrated in TBST for few minutes and then blocked in 5% non-fat milk 
overnight at 4 
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Immunoblotting of membranes 
Membrane was washed with TBST for 3 times, 5 minutes each. Then it 
was incubated with first anti-bodies for four hours at room temperature. 
After that, the membrane was washed with TBST for four times and 
respectively washed for 10 minutes, 5 minutes, 5 minutes, 5 minutes. The 
membranes were then incubated with second anti-bodies for 1 hour at 
room temperature. After that, membranes were washed with TBST for 
three times, 5 minutes each. 
Exposure of membranes 
Enhanced chemiluminescence system solution (ECL) (Amersham 
Biosciences, Buckinghamshire, UK) was employed and the working 
solution is a mixture of Buffer A and Buffer B with 1:1 proportion. 
Membranes were incubated with 1.5 ml of ECL for 1 minute and the 
excess ECL solution was then drained away. Membranes were wrapped 
with Saran-wrap and settled down in an x-ray film cassette. After that, 
Hyperfilm™ (Amersham Biosciences Buckingham-shire, UK) was placed 
onto the membrane in dark room for few minutes, depending on the signal 
intensity. Finally, the film was developed in a film processor. 
2.6. Statistical analysis 
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The data were presented as means 土 SD for at least three independent trials 
for each group. Differences between groups were examined for statistical 
significance using Student's t test or one-way ANOVA followed by 




Roles of HO-1 in gastric cancer cells treated by 5-FU 
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3.1. Cell proliferations with drug treatments 
3.1.1. MTT assay 
3.1.1.1. Introduction 
The pyrimidine antimetabolite 5-FU is one of the first-line treatment 
options for gastric cancers(Wilk:e, Preusser et al. 1990; Tsujinaka, Kido et 
al. 1992). 5-FU is able to suppress the DNA and RNA replication as a 
pyrimidine analogue; the cytotoxicity of 5-FU can be selectively displayed 
in cancer cells which proliferate much faster than normal cells. However, 
the anticancer efficacy of 5-FU is clinically limited due to chemoresistance 
attributed to a number of cellular mechanisms(Baldini 1997; Kirsch and 
Kastan 1998). 
Heme oxygenase-1 (HO-1) is considered as a cytoprotective enzyme due 
to its anti-oxidative and anti-inflammatory function. Furthermore,, it is 
illustrated that HO-1 plays pro-angiogenesis roles in the development of 
various cancers. Here we inhibit the expression of HO-1 to investigate 
whether there is a synergic or additive effect between 5-FU and HO-1 
inhibitor on cytotoxicity in cancer cells. Zinc protoporphyrin-lX (ZnPP) 
was used as HO-1 inhibitor. MTT assay was applied to detect the 
proliferation of gastric cancer cell lines MKN28 and MKN45 after 
treatment with 5-FU, or ZnPP, or 5-FU plus ZnPP. 
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3.1.1.2.Method and results 
MKN28 and MKN45 were planted into 96xwell plates. Different 
concentrations of 5-FU as well as ZnPP were tested in both cell lines for 
12 h, 24h, 48h, and 72h. 5-FU were tested from the concentrations of 
ImM to lO^M (ImM, 500^iM, 250^M, lOO^M, lO^M) while ZnPP was 
tested from 40^M to O.Ol^M ( 40^M, 20^iM, lO^iM, l^iM, 0.1 ^iM, 
0.01 ^M), referring to the ones reported by others (Hirai, Sasahira et al, 
2007; Sasaki, Tominaga et al. 2007). MTT assay was conducted by the 
procedure described in 2.2.1. Differences between groups were examined 
for statistical significance using one-way ANOVA. Two-way ANOVA 
was used to examine the interaction of the two drugs 5-FU and ZnPP in 
both cell lines. 
From our experiments, we observed that the viability of MKN28 and 
MKN45 cells were significantly reduced by 5-FU in time-dependent 
manners (Fig 3.1). The dependence on doses of 5-FU was not significant 
observed in both cells in our experiments which may due to the narrow 
range of trial concentrations. MKN45 cells with wild p53 were more 
sensitive to the cytotoxicity of 5-FU than MKN28 cells with mutant p53; 
such difference between the two cell lines was increased with the duration 
of the treatment ( Fig 3.1 D) 
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The viability of MKN28 and MKN45 was both reduced by HO-1 inhibitor 
ZnPP ； the reduction was time- and concentration-dependent ( Fig 3.2.). 
There is no significant difference between the two cell lines in response to 
ZnPP treatment. 
Based on our results, we chose 100 [iM 5-FU and 1 |iM ZnPP as the 
optimal concentrations in the combined treatment. Shown as the Fig 3.3, 
the viability of both cell lines was significantly reduced by the co-
treatment with 5-FU plus ZnPP, which reduced cell viability 20% more 
than 5-FU treatment alone in MKN28 and 15% in MKN45. It could also 
be referred that the cytotoxicity of 5-FU was strengthened by ZnPP and the 
sensitivity of both cell lines to 5-FU was significantly enhanced by 
inhibiting HO-1. As the effect of the association of 5-FU and ZnPP on 
both cells was less than the sum of the effect caused by each drug alone 
(Fig 3.3. A and B), the significant enhancement of cytotoxity by 5-FU plus 
ZnPP should be considered as an additive effect of both drugs. 
From the MTT results, we conclude that the treatment with 5-FU plus 
ZnPP could reduce the proliferation of MKN28 as well as MKN45. 
However, we still have no information about the dead cells: which types of 
cell death were increased, apoptosis, oncosis or autophagy? As this 
question is mostly related to the chemotherapy in clinical use, we thus 
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conducted another assay to investigate cell death, especially apoptosis, 
after the drug treatment. 
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Fig.3.1. Effects of 5-FU on the viability of human gastric cancer cells. 
Gastric cancer cells ( MKN28 with mutant p53 and MKN45 with wild p53) 
were treated with 5-FU 400nM, 250^M, 200|iM, 150|iM, lOO i^M, 50 ^M 
for 24h, 48h and 72h. Cell viability was measured by the MTT assay and 
expressed as % of control culture conditions ( 0}j,M 5-FU ). The data were 
represented as mean 土 SD for six replicate determinations for each 
treatment. Experiments were repeated three times with similar results. A: 
treatment in both cell lines with different concentrations of 5-FU for 24h; 
B: treatment in both cell lines with different concentrations of 5-FU for 
48h; C: treatment in both cell lines with different concentrations of 5-FU 
for 72h; D: time-response curve for the treatment with 100 |iM 5-FU in 
both cell lines. 
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Fig.3.2. Effects of HO-1 inhibitor ZnPP on the viability of human gastric 
cancer cells. Gastric cancer ceils ( MKN28 with mutant p53 and MKN45 
with wild p53) were treated with lOO^M, lO^iM, l^M, O.OlfiM, 0.1 nM 
ZnPP for 24h, 48h and 72h. Cell viability was measured by the MTT assay 
and expressed as % of control culture conditions ( 0|j,M ZnPP ). The data 
were represented as mean 士 SD for six replicate determinations for each 
treatment. Experiments were repeated three times with similar results. A: 
treatment in both cell lines with different concentrations of ZnPP for 24h; 
B: time-response curve for treatment of both cell lines with IfxM ZnPP. 
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Fig.3.3. Effects of combined treatment with 5-FU and ZnPP on the 
viability of human gastric cancer cells. Gastric cancer cells ( MKN28 with 
mutant p53 and MKN45 with wild p53) were respectively treated with 
l^iM ZnPP, 100 a^M 5-FU as well as 5-FU plus ZnPP for 24h, 48h and 72h. 
Cell viability was measured by the MTT assay and expressed as % of 
control culture conditions ( O i^M ZnPP and 5-FU ). The data were 
represented as mean 土 SD for six replicate determinations for each 
treatment. Experiments were repeated three times with similar results. A: 
treatment of MKN28; B: treatment of MKN45. * p < 0.05, compared with 
control, A p< 0.05, compared with the treatment with 5-FU alone. 
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3.1.2 TUNEL assay 
3.1.2.1. Introduction 
Apoptosis plays an essential role in cell proliferation in various tumors and 
is associated with turnover of normal cells into malignantly proliferated 
tumor cells. Resistance toward apoptosis is a hallmark of perhaps all types 
of cancers, which have been identified from studies in animal models and 
cultured cells, as well as from descriptive analyses of human tumor 
biopsies (Hanahan and Weinberg 2000). There is also increasing evidence 
showing that the induction of apoptosis is an effective mediation to stop 
unchecked growth of gastric cancer cells (Wakana, Kasuya et al. 2002; Wu, 
Xia et al. 2003).Anticancer drugs exert their functions of cytotoxicity by 
various mechanisms to stimulate apoptosis of cancer cells rather than 
increasing necrosis or degeneration (Sugamura, Makino et al. 1997). 
5-FU induces apoptosis of tumor cells in Chinese hamster ovary cells 
(Barry, Behnke et al. 1990) and apoptosis in the crypt of the small intestine 
in a mouse model (Ijiri and Potten 1987). It has been reported that a bolus 
administration of 5-FU induces a higher rate of apoptosis in normal tissues 
of the thymus, spleen, and ileum than infusion for 72 hours (Sakaguchi, 
Stephens et al. 1994). Sugamura reported that 5-FU could significantly 
induce apoptosis of gastric cancer cells (Sugamura, Makino et al. 1997). 
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Here we applied TUNEL to assay cell apoptosis. We intended to 
investigate the effect of 5-FU and ZnPP on the cell death of two gastric 
cancer cell lines MKN28 and MKN45. We were also interested in the 
effect of the co-treatment of 5-FU plus ZnPP on the both types of cells. 
3.1.2.2 Method and results 
MKN28 and MKN45 were planted into 96-well plates and then treated 
with lOO i^M 5-FU, l^iM ZnPP or both for 12h, 24h, 48h or 72h. TUNEL 
assay was processed as the above mentioned method ( please refer to 2.2.2 
for the method). 
The large number of DNA fragments appearing in apoptotic cells results in 
a multitude of 3'-hydroxy 1 termini of DNA ends which provide for the 
single step fluorescent labeling and then be detected by flow cytometric 
method. Non-apoptotic cells do not incorporate significant amounts of the 
F-dUTP owing to the lack of exposed 3'-hydroxy 1 DNA ends. Apoptosis 
was highly increased in MKN28 and MKN45 after the treatment with 5-
FU for 48h, and the increase of apoptosis was enhanced by the addition of 
ZnPP in MKN45 but it was not significantly observed in MKN28. The 
treatment with ZnPP alone had little effect on inducing apoptosis in both 
cell lines. The TUNEL results obtained in the cells treated for 48h were 
shown in Fig.3.4. . 
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B TUNEL assay for MKN45 after drug treatments for 48h 
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Fig 3.4. Effects of 5-FU and ZnPP on apoptosis of MKN28 and MKN45 
cells. Cells were treated with l | iM ZnPP, lOO i^M 5-FU or the combination 
of the both drugs for 48h. Apoptosis was assayed by TUNEL using Flow 
Diagram of APODIRECT™ APOPTOSIS ASSAY kit as described before 
(seen in 2.2.2). A: TUNEL assay for MKN28 cells; B: TUNEL assay for 
MKN45 cells; C: The proportion of the apoptotic cells of both cell lines, 
represented by the relative fold of the control group. Experiments were 
repeated twice with similar results. 
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3.2. HO-1 expression in cells treated with 5-FU and ZnPP 
3.2.1. Introduction 
HO-1 is associated with a wide variety of physiological and pathological 
processes. Many existing studies reported that HO-1 in tissues plays a role 
against oxidative stress (Poss and Tonegawa 1997) and inflammation 
(Otterbein, Bach et al. 2000; Sawle, Foresti et al. 2005)，but in favor of 
angiogenesis (Nishie, Ono et al. 1999). The effect of HO-1 on the 
regulation of cell proliferation has also been demonstrated in various types 
of cells (Clark, Green et al. 1997). 
What is the role of HO-1 in the anti-tumor treatment of gastric cancer? 
Could the inhibition of HO-1 enhance the sensitivity of gastric cancer cells 
to the chemotherapeutic agents? Form the above MTT and TUNEL results, 
we knew that the cytotoxicity of 5-FU was enhanced by HO-1 inhibitor 
ZnPP. However, we cannot confirm whether 1 |aM ZnPP was able to 
inhibit the expression of HO-1; we also did not know whether 5-FU had an 
effect on the expression of HO-1 in MKN45 and MKN28. Obviously more 
work needs to be done to investigate the effect of the co-treatment with 5-
FU and ZnPP on the HO-1 expression in both cell lines. Hence western 
blotting was applied to detect the expression of HO-1. 
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3.2.2. Method and results 
MKN28 and MKN45 were planted into 100mm dishes and cultured with 
various treatments. Total protein was extracted and analyzed by Western 
blotting ( please refer to 2,5 for the method). The densities of the 
corresponding protein bands were determined with the Molecular Imager 
and Imaging Densitometer from Bio-Rad Laboratories (Hercules, CA, 
USA). 
The result showed that ZnPP was able to effectively inhibit the HO-1 
expression in both cell lines in a time- and concentration-dependent 
manner. The expression of HO-1 in MKN28 was higher than that in 
MKN45 ( Fig 3.4. and Fig 3.5.) and 5-FU could induce the expression of 
HO-1 in both gastric cancer cell lines in a concentration-dependent manner, 
especially when the concentration of 5-FU reached 1000 ^M (Fig 3.6). 
Based on the Western blotting results as well as the above MTT results, we 
treated cells with 100 ^M 5-FU and 1 fiM ZnPP in combination for 24h. 
The Western blotting results indicated that HO-1 expression in both cell 
lines was significantly inhibited by 100 |iM ZnPP at 24h after the 
treatment. However, its level was induced by 1 i^M 5-FU. The co-
treatment with 5-FU plus ZnPP significantly reduced the expression of 
HO-1, compared with the treatment of 5-FU alone. 
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Fig 3.5. The concentration-course and time-course of HO-1 expression in 
MKN28 treated with ZnPP. MKN28 cells were cultured in completed 
medium for 24h and then (a) exposed to 1 ^M, 10 |iM, 20 |iM or 40 |iM 
ZnPP for 24h; (b) exposed to 1 ^M ZnPP for 24h, 48h or 72h. Total 
protein was extracted and analyzed by Western blotting. The densities of 
the corresponding protein bands were determined with the Molecular 
Imager and Imaging Densitometer from Bio-Rad Laboratories (Hercules, 
CA, USA) 
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Fig 3.6. The concentration-course and time-course of HO-1 expression in 
MKN45 treated with ZnPP. MKN45 cells were cultured in completed 
medium for 24h and then (a) exposed to 1 ^M, 10 |iM, 20 i^M or 40 ^M 
ZnPP for 24h; (b) exposed to 1 i^M ZnPP for 12h or 24h. Total protein 
was extracted and analyzed by Western blotting. The densities of the 
corresponding protein bands were determined with the Molecular Imager 
and Imaging Densitometer from Bio-Rad Laboratories (Hercules, CA, 
USA) 
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Fig 3.7. The concentration-course of HO-1 expression in MKN28 and 
MKN45 after the treatment with 5-FU. Cells were cultured in completed 
medium for 24h and then exposed to 10 |iM, 100 |iM or 1000 ^M 5-FU 
for 24h. Total protein was extracted and analyzed by Western blotting. The 
densities of the corresponding protein bands were determined with the 
Molecular Imager and Imaging Densitometer from Bio-Rad Laboratories 
(Hercules, CA, USA), (a) MKN28 treated with different doses of 5-FU; (b) 
MKN45 treated with different doses of 5-FU. * P < 0.05, compared with 
control. 
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Fig 3.8. HO-1 expression in MKN28 and MKN45 after the various 
treatments. Cells were cultured in completed medium for 24h and then 
exposed to 100 ^M 5-FU, 1 i^M ZnPP or the both drugs for 24h. Total 
protein was extracted and analyzed by Western blotting. The densities of 
the corresponding protein bands were determined with the Molecular 
Imager and Imaging Densitometer from Bio-Rad Laboratories (Hercules, 
CA, USA), (a) MKN28; (b) MKN45 “++’’ represents the treatment of 
100 i^M 5-FU plus 1 i^M ZnPP. 
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3.3 Discussion 
5-fluorouracil (5-FU) is the most widely used anti-gastric cancer 
chemotherapy drug (Wilke, Preusser et al. 1990; Tsujinaka, Kido et al. 
1992)and the core of classical chemotherapeutic regimes. However, the 
anticancer efficacy of 5-FU is clinically limited due to chemoresistance 
contributed by a number of cellular mechanisms(Baldini 1997; Kirsch and 
Kastan 1998). 5-FU is also poorly tolerated in patients because of its 
various side effects, such as diarrhea, bruising or bleeding, anaemia, 
nausea and vomiting, tiredness, taste changes, lowered resistance to 
infection, hair loss, sensitivity of the skin to sunlight, etc. Recently, 
targeted therapy has been developed in anticancer treatments. Proteins 
associated with specific pathways for cancer transformation and 
progression (e.g., apoptosis, angiogenesis, cell-cycle regulation, signal 
transduction, and invasion) are investigated. Traditional chemotherapeutic 
agents combined with inhibitors of these targeted proteins can effectively 
inhibit the proliferation of cancer cells while the required dose of 
chemotherapeutic agents could also be reduced, so that the effectiveness of 
the treatment can be improved and the side effect reduced. The quality of 
patients' lives may therefore be benefited from the new strategy to 
combine the targeted therapy with traditional chemotherapeutic agents. 
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Heme oxygenase-1 (HO-1) is the rate-limiting enzyme in the degradation 
of heme and inducible by a variety of stimuli such as heat shock, oxidative 
stress, hypoxia, hyperoxia, ultraviolet, inflammatory cytokines. Due to the 
inducibility of HO-1, it plays an essential but complicated role in 
physiological and pathological processes. To date, it is generally 
considered that it is a protein with functions of anti-oxidation, anti-
inflammation, pro-angiogenesis and regulating cell proliferation. The level 
of HO-1 is known to be increased in a number of tumors and its inhibition 
leads to the decreased growth of tumor cells (Deininger, Meyermann et al. 
2000; Torisu-Itakura, Fume et al. 2000; Lo, Lin et al. 2007). Therefore, 
HO-1 can be a good molecule for targeted therapy. Unfortunately, the role 
of HO-1 in the treatment of gastric cancer has not been studied before. We 
therefore, employed two gastric cancer cell lines MKN28 with mutant p53 
and MKN45 with wild p53 to examine how HO-1 inhibition affects the 
response of the tumor cells to 5-FU treatment. We have shown that both 
gastric cancer cells tested expressed HO-1 and the level of HO-1 could be 
significantly inhibited by a specific HO-1 inhibitor ZnPP. 
Our results showed that the viability of both types of gastric cancer cells 
were reduced by 5-FU in a time-dependent manner. MKN45 cells with 
wild p53 were more sensitive to the cytotoxicity of 5-FU than MKN28 
cells with mutant p53, which is consistent with the report that gastric 
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cancer cells with mutant-type p53 were less responsive to 5-FU treatment 
than those with wild-type p53 (Matsuhashi, Saio et al. 2005). It is 
noteworthy that the expression of HO-1 was increased rather than being 
inhibited by 5-FU, as evident by the Western blotting analysis. 
Considering that the function of HO-1 is to aid proliferation and growth of 
cells, 5-FU-induced HO-1 overexpression is likely to be a compensatory 
mechanism of the tumor cells to reduce the damage. In such a scenario, the 
proliferation and growth of the cells should be further suppressed if HO-1 
is blocked. Therefore, it may be possible to apply HO-1 inhibitors to 
enhance the cytotoxic effect of 5-FU. Our experimental data showed that 
HO-1 inhibitor ZnPP itself could markedly reduce the viability of MKN28 
and MKN45 cells. In the presence of ZnPP, the 5-FU-induced HO-1 
expression was blocked and the proliferation of both tumor cells was 
clearly reduced. Therefore, the combination of both 5-FU and HO-1 
inhibitor ZnPP kills much more tumor cells than either agent alone. Such a 
combination may help reduce the dose of 5-FU and thus lower the side 
effect associated with 5-FU therapy in clinical setting. 
It is concluded that (1) ZnPP was an effective HO-1 inhibitor, which was 
in consistence with the report from Maines (Maines 1981); 2) HO-1 is 
positively associated with the proliferation of both types of gastric cancer 
cells; 3) MKN28 with mutant-type p53 were less responsive to 5-FU 
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treatment than MKN45 with wild-type p53; 4) The expression of HO-1 
can be induced by 5-FU in a time- and concentration-dependent manner, 
and such an induction of HO-1 expression by 5-FU is likely to be a 
protective self-feedback of cancer cells in response to 5-FU-mediated 
damage; 5) 5-FU and HO-1 inhibitor ZnPP in combination are much more 
effective in killing gastric cancer cells than either agent alone; In other 
words, the sensitivity of gastric cancer cells to chemotherapeutic drugs 
such as 5-FU can be enhanced by the inhibition of HO-1, which makes 
HO-1 as a potentially targeted protein in anti-gastric cancer therapy. 
In order to elucidate the biochemical mechanism involved in the additive 
effect of 5-FU and ZnPP, we have conducted several experiments which 
are detailed in next chapter. 
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Chapter Four 
Mechanism responsible for the additive effect of 
5-FU and ZnPP 
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4.1. Cell cycle arrest after drug treatments 
4.1.1. Introduction 
Most chemotherapeutic agents play roles in anti-growth of cancer cells 
with variations of cytotoxic effect in the cell cycles. Among the four 
distinct phases in cell cycle, G1 phase is marked by enzymes synthesis; S 
phase is for DNA synthesis, in which cells are highly proliferating; G2 
phase is for protein synthesis; in M phase chromosomes and cytoplasm are 
divided into two daughter cells. Furthermore, there is a state of quiescence 
of cells called GO phase, on which phase cells are not undergoing 
proliferation. Chemotherapeutic agent 5-FU emphasizes on the S-phase 
cells while also act throughout the cell cycle varying from the types of 
cells. 
Our MTT and TUNEL results have demonstrated that the cytotoxicity of 
5-FU can be enhanced by inhibiting HO-1 and induction of apoptosis by 
the treatment of 5-FU plus ZnPP is much greater than by 5-FU alone. 
However, we still did not fully understand the pathway by which 5-FU and 
ZnPP affect on the cell cycle of both types of gastric cancer cells. We 
wondered whether the combined treatment could arrest gastric cancer cells 
at the non-mitosis phases to prevent them from entering mitosis. Here we 
applied flow cytometry to analyze cell cycle and to investigate the effect of 
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5-FU and ZnPP on cell cycle regulation of both gastric cancer cell lines 
MKN28 and MKN 45. 
4.1.2. Method and results 
MKN28 and MKN45 cells were planted into 6 x well plates and then 
treated with 100 ^M 5-FU, 1 ^M ZnPP or the combination of the both 
drugs for 12h, 24h, 48h. After that, cells were collected for cell cycle assay 
by flow cytometry (please refer to 2.3 for the method in detail). 
As shown in Fig 4.1.A and Fig 4.2.A，100 i^M 5-FU arrested both types of 
gastric cancer cells in the Gl/GO-phase, reduced cells in the S-phase, 
blocked cells entering the G2/M-phase, leading to less cells being released 
to mitosis. 1 j^ M ZnPP mainly caused Gl/GO-phase arrest and reduced 
cells in the S-phase in both cell lines. Cells that had passed through the S-
phase were blocked in the G2/M-phase by ZnPP and thus the peak of 
G2/M-phase showed slightly higher than that in the control group. The 
combination of 5-FU with ZnPP enhanced the GO/Gl arrest caused by 5-
FU in both cell lines and it also had different effects on the S-phase and 
G2/M-phase between the two cell lines. In the MKN28, the reduction of 
cells in the S-phase was enhanced by the addition of ZnPP while the 
reduction of cells in the G2/M-phase was partly counteracted. In the 
MKN45, the addition of ZnPP mainly enhanced the reduction of cells in 
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the G2/M phase caused by 5-FU, and it also offset the reduction of cells in 
the S-phase. However, no matter which phase of cell cycle the addition of 
ZnPP mainly effect on in the both types of cells, it did block cells into 
G2/M-phase by enhancing the GO/Gl arrest and, eventually, reduced cells 
undergoing mitosis. In addition, the addition of ZnPP increased in both 
cell lines the number of cells in SubGl which represent apoptotic cells that 
escape from the normal cell cycle (Fig 4.1.B and Fig 4.2 B). The finding 
was consistent with our previous TUNEL results. 
76 
Cell cycle analysis of NKN28 
140.00% n _ * 
b 120.00% 
o j J » 
“100.00% - — 1 * 
S • • 4c n B Control 
A I 80.00% • • * I •ZnPP 
§ 60.00% - • • n • °5Fu 
H H — • nZnPP&SFu 
® 40.00% • • • ‘ •• • 
0.00% I—I , _ • _ • I 
G0-G1 G2-M S-phase 
Cell cycle phase 
Cell cycle analysis of apoptosis in 
MKN28 
一 350.00% * 
0 
1 300.00% -
® o 250.00% - • " 1 ^ B Control 
2 200.00% - • ZnPP I 
I 1 5 0 . 0 0 % 二 H M 0 5 F U 
$ • ZnPP&5Fu 
: 1 0 0 . 0 0 % ； ‘ 
^ 0 . 0 0 % ； ^ 
SubG1 phase 
77 
Fig 4.1. Effect of drug treatments on cell cycle of MKN28. MKN28 cells 
were treated with l^M ZnPP, 100 ^M 5-FU or the combination of 100 jiM 
5-FU with 1 ^M ZnPP for 12h. The number of cells in GO/Gl, G2/M, S-
phases and SubGl was determined by flow cytometry after staining the 
cells with PI. The proportion of the each cell phase was determined 
relative to 12h cells without any drug treatment. Values are mean 士 SD of 
three experiments. A: cell cycle phases in MKN28; B: apoptotic cells/ cells 
in SubGl in MKN28. *P<0.05, compared with the control group. 
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Fig 4.2. Effect of drug treatments on cell cycle of MKN45. MKN45 cells 
were treated with l|xM ZnPP, 100 |iM 5-FU or the combination of 1 |iM 
ZnPP with 100 i^M 5-FU for 24h. The number of cells in GO/Gl, G2/M, S-
phases and apoptosis was determined by flow cytometry after staining the 
cells with PI. The proportion of the each cell phase was determined 
relative to 12h cells without any drug treatment. Values are mean ± SD of 
three experiments. A: cell cycle phases in MKN45; B: apoptosis in 
MKN45. *P<0.05, compared with the control group. 
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4.2. Mitochondrial dependent and independent pathways 
4.2.1. Introduction 
Mitochondria, which are small, membrane-bound structures, are the source 
of the reactions generating most energy needed for cell life activities. A 
great deal of evidence show that the mitochondria is at the central stage of 
cell apoptosis(Zamzami, Marchetti et al. 1995; Zamzami, Marchetti et al. 
1995; Green and Reed 1998) . Mitochondria can trigger cell apoptosis by 
(i) disrupting electron transport, oxidative phosphorylation and adenosine 
triphosphate (ATP) generation(Eguchi, Shimizu et al. 1997; Garcia-Ruiz, 
Colell et al. 1997)，(ii) releasing pro-apoptotic proteins to activate caspase 
family proteases (Newmeyer, Farschon et al. 1994; Liu, Kim et al. 1996; 
Li, Nijhawan et al. 1997)，and (iii) altering cellular reduction-oxidation 
(redox) potential (Garcia-Ruiz, Colell et al. 1997). 
The central role of the mitochondria in apoptosis is initially observed from 
the alteration in their membrane potential in response to apoptotic 
stimuli (Zamzami, Marchetti et al. 1995; Zamzami, Marchetti et al. 1995). 
Death-activating signals induce the alteration of the mitochondrial 
membrane potential, which is followed by the release of apoptosis-relating 
molecules such as apoptosis-inducing factor (AIF), endonuclease-G, 
Smac/Diablo, and cytochrome c. Anti-apoptotic Bcl-2 family members 
(Bcl-2, Bcl-XL) can block these mitochondrial events, whereas pro-
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apoptotic Bcl-2 family members (Bax, Bak, Bad) can trigger these changes. 
Cells undergoing early apoptosis in a mitochondrial-dependent pathway 
usually show a loss of the mitochondrial membrane potential 
(Vayssiere, Petit et al. 1994; Zoratti and Szabo 1995). Thus the reduction 
of A平;„ is used as a recognized marker for early apoptosis(Green and Reed 
1998). 
From the above MTT as well as TUNEL results, it is evident that cell 
proliferation of both gastric cancer cell lines MKN28 and MKN45 could 
be significantly inhibited after the treatment with 5-FU plus HO-1 inhibitor 
ZnPP, compared with the treatment with either 5-FU or ZnPP alone. The 
inhibition of HO-1 could enhance the cytotoxicity of 5-FU by inducing 
more apoptosis. However, whether the apoptosis is related to the 
mitochondria is still not known. Here we applied flow cytometry to 
measure the mitochondrial membrane potential. We intended to investigate 
whether there would be an alteration of the mitochondrial membrane 
potential during the treatment and whether there would be a significant 
difference between 5-FU and 5-FU plus HO-1 inhibitor ZnPP. 
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4.2.2. Method and results 
MKN28 and MKN45 cells were planted into 6 x well plates and treated 
with 100 jiM 5-FU, 1 j^ M ZnPP or the combination of the both drugs for 
3h, 6h, 12h, 24h, 48h. After that, cells were collected for cell cycle assay 
by flow cytometry (please refer to 2.4 for the method in detail). 
As shown in Fig 4.3, the proportion of MKN28 cells with reduced 
mitochondrial membrane potential of MKN28 was increased after the 
treatment with 100 i^M 5-FU plus 1 )aM ZnPP for 6h while the induction 
in MKN45 cells could be observed after the combined treatment for 3h. 
The treatment with 5-FU plus ZnPP could significantly increase the 
~ proportion of MKN28 and MKN45 cells with reduced mitochondrial 
membrane potential respectively by 1.94 and 1.55 fold of control, 
indicating that the combined treatment was more powerful in reducing the 
mitochondrial membrane potential of both cell lines. Therefore, the 
addition of ZnPP could trigger more apoptosis in the mitochondrial-
dependent pathway. 
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B The mitochondrial membrane potential of MKN45 after drug 
treatment for 3h 
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C Mitochondrial membrane potential of gastric cancer cells 
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Fig 4.3. Effects of drug treatments on the mitochondrial membrane 
potential. Both types of cells were treated with l^iM ZnPP, 100 i^M 5-FU 
or the treatment of 100 i^M 5-FU plus 1 i^M ZnPP for different hours and 
the significant alteration was detected at 6h in MKN28 while 3h in 
MKN45 (shown in the above figure). The mitochondrial membrane 
potential was determined by flow cytometry after staining the cells with 
DiOC6. The mitochondrial membrane potential after treatments was 
compared with the mitochondrial membrane potential of the control group. 
Values are mean of three experiments. A: mitochondrial membrane 
potential in MKN28; B: mitochondrial membrane potential in MKN45; C: 
the proportion of the mitochondrial membrane potential of both cell lines, 
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represented by the relative fold of the control group. Experiments were 
repeated with two times with similar results. 
4.3. Alteration of apoptotic proteins in gastric cancer cells after drug 
treatments 
4.3.1. Introduction 
Apoptosis is a fundamental biochemical cell-death pathway essential for 
normal tissue homeostasis, cellular differentiation and development. Most 
of the occurrences of apoptotic cell deaths require the activation of a 
family of cysteine proteases with specificity for aspartic acid residues, 
named as caspases (Alnemri, Livingston et al. 1996). Until now, 14 
mammalian caspase family members have been described. Caspases play a 
pivotal role in the execution of apoptosis. They are present in cells as 
inactive procaspases; a variety of apoptotic stimuli can at first activate 
some procaspases, such as caspase-2, caspase-8, caspase-9 and caspase-10, 
and then such activated caspases in turn activate the executioner caspases, 
including caspase-3, caspase-6 and caspase-7. Therefore, these caspases 
can be auto-catalytically activated in a cascade of enzymatic chain 
reactions (Shi 2004), which in turn amplify apoptotic signals. The 
activated executioner caspases can cleave a variety of target proteins, 
disrupt essential processes in cells, damage cell components and finally 
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lead to fast and irreversible apoptosis(Nicholson and Thomberry 1997). 
Among these caspases, caspase-3 is an important executioner caspase. Its 
activation begins when caspase-9 binds to Apoptotic protease activating 
factor-1 (Apaf-1) in a cytochrome c- and dATP-dependent fashion(Li, 
Nijhawan et al. 1997). Binding activates caspase-9 and the activated 
caspase-9 in turn cleaves pro-caspase-3 (32kDa) into two subunits (20kDa 
and 12kDa)(Nicholson, Ali et al. 1995). The activated caspase-3 leads to 
cleavage of the 45kDa subunit of DNA fragmentation factor (DFF-45), 
which in turn triggers a pathway leading fragmentation of genomic DNA 
to nucleosomal fragments, a hallmark of apoptosis(Liu, Zou et al. 1997). 
Cytochrome c is an essential factor required for the activation of caspases. 
It is normally present in the mitochondria and cannot activate apoptosis 
(Yang, Liu et al. 1997). In response to a variety of stimuli of apoptosis 
such as serum withdrawal, activation of Fas, treatment with ionization, and 
numerous pharmacological agents, cytochrome c is released from the 
mitochondria to the cytosol (Liu, Kim et al. 1996; Yang, Liu et al. 1997)， 
where it binds to Apaf-1 (Zou, Henzel et al. 1997). Cytochrome c/Apaf-1 
complex allows caspase-9 to bind in the presence of dATP; the binding 
converts caspase-9 into a active protease and therefore activates caspase-3 
(Li, Nijhawan et al. 1997). 
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While most apoptosis require the participation of caspases, there are some 
exceptions in which the activation of caspases are not necessarily needed 
for apoptosis. The mitochondrial released pro-apoptotic molecules such as 
apoptosis-inducing factor (AIF) can bypass caspases to trigger apoptosis 
by translocating into the nucleus and binding to DNA (Susin, Zamzami et 
al. 1996). AIF is first identified as a protein involved in the caspase-
independent apoptosis due to the discovery that the activity can not be 
blocked by zVAD-fmk, a general caspase inhibitor(Susin, Lorenzo et al. 
1999). Confocal and electron microscopy have demonstrated that AIF in 
normal cells is strictly confined to the mitochondria and thus colocalizes 
with heat shock protein 60 (hsp60). AIF can be activated by the cleavation 
of calpain in response to proapoptotic stimuli. The activated AIF is then 
translocated from the mitochondria to the cytosol and finally to the nucleus, 
where AIF causes a chromatin condensation and DNA fragmentation in a 
caspase-independent manner(Susin, Lorenzo et al. 1999; Ye, Cande et al. 
2002; Otera, Ohsakaya et al. 2005; Polster, Basanez et al. 2005; Yuste， 
Moubarak et al. 2005). Although a recent study has demonstrated that AIF 
can suppress chemical-stress induced apoptosis of colon cancer cells due 
to its oxidoreductase activity(Urbano, Lakshmanan et al. 2005). It is 
generally considered that AIF plays an important role in the death of 
cancer cells, such as ameloblastomas (Kumamoto and Ooya 2005), lung 
carcinomas(Gallego, Joseph et al. 2004) and human gastric epithelial 
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carcinoma(Park, Cho et al. 2005). It is also reported that genetic 
inactivation of AIF renders embryonic stem cells resistant to cell death 
after serum starvation (Joza, Susin et al. 2001). 
From our results mentioned in chapter 3, we know that the inhibition of 
HO-1 by ZnPP enhanced the sensitivity of gastric cancer MKN28 and 
MKN45 cells to 5-FU. In order to explore biochemical mechanisms of the 
additive effect between 5-FU and ZnPP, we investigated the expression of 
several apoptosis-relating proteins in the gastric cancer cells MKN28 and 
MKN45. 
4.3.2. Methods and results 
MKN28 and MKN45 cells were planted into 100mm dishes and treated 
with 1 |iM ZnPP, 100 |iM 5-FU, or the combination of the both drugs for 
24h. Total protein was extracted for pro-caspase-3 detection while 
mitochondrial and cytosolic protein was extracted for the detection of 
cytochrome c and AIF (please refer to 2.5.2.2 for the method in detail). 
Western Blotting results showed that pro-caspase-3 in both cells was 
obviously reduced by the addition of ZnPP, compared with the treatment 
of 5-FU alone, indicating that activated caspase-3 was induced to a much 
higher level by the combined treatment than by 5-FU alone. Therefore, the 
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inhibition of HO-1 might enhance the apoptosis-inducing ability of 5-FU 
in both gastric cancer cell lines partly by stimulating the activation of 
caspase-3. This finding also indicated that the combined treatment with 5-
FU and ZnPP induced apoptosis of MKN28 and MKN45 cells in a 
caspase-related pathway 
It is known that cytochrome c would translocate from the mitochondria to 
the cytosol upon the stimulation of apoptotic signals. Our results showed 
that the cytosolic cytochrome c was increased after the treatment with 5-
FU plus ZnPP in MKN45, compared with the treatment of 5-FU alone. 
Considering this finding together with our data on the mitochondrial 
membrane potential of MKN45, it is clear that the combined treatment of 
5-FU and ZnPP induces apoptosis by reducing stimulating the 
release of cytochrome c into the cytosol, and activating caspase-3 in 
MKN45. 
The induced expression of cytosolic cytochrome c was not obviously 
detected in MKN28. However, AIF was translocated from the 
mitochondria to the cytosol after the combined treatment in MKN28, 
which did not occur in the cells treated with 5-FU alone. It is well known 
that the translocation of AIF from the mitochondra to the cytosol and 
subsequently the nucleus is a key process in a caspase-independent 
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apoptosis. It is therefore likely that accompanying the reduction of A中;„ in 
MKN28, AIF is released from the protein-permeable mitochondria to the 
cytosol in response to the treatment with 5-FU plus ZnPP,suggesting that 
caspase-independent apoptotic mechanism has been triggered by the 5-FU 
and HO-1 inhibitor ZnPP in combination. 
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Fig 4.4. The expression of pro-caspase-3 in MKN28 and MKN45. Cells 
were cultured in completed medium for 24h and then exposed to 1 i^M 
ZnPP, 100 ^M 5-FU, or the combination of the both drugs for 24h. Total 
protein was extracted and analyzed by Western blotting. The densities of 
the corresponding protein bands were determined with the Molecular 
Imager and Imaging Densitometer from Bio-Rad Laboratories (Hercules, 
CA, USA) a: protein expression in MKN28; b: protein expression in 
MKN45 
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e Cytochrome C expression in MKN45 
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Fig 4.5. The expression of AIF and cytochrome c in MKN28 and MKN45. 
Cells were cultured in completed medium for 24h and then exposed to 1 
|iM ZnPP, 100 }iM 5-FU, or the combination of the both drugs for 24h. 
Mitochondrial protein and cytosolic protein were extracted and analyzed 
by Western blotting. The densities of the corresponding protein bands 
were determined with the Molecular Imager and Imaging Densitometer 
from Bio-Rad Laboratories (Hercules, CA, USA) c: mitochondrial AIF 
expression in MKN28; d: cytosolic AIF expression in MKN28; e: 
cytosolic cytochrome c expression in MKN45 
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4.4. Discussion 
There is an increasing body of literature describing the role of HO-1 in a 
wide variety of physiological and pathological processes, including 
chronic obstructive lung disease, hypoxic/ischemic injury, transplant 
rejection, and cancer. Some experiments have shown that HO-1 plays a 
role of negative growth regulator of epithelium (Aizawa, Ishizaka et al. 
2001), astroglia (Song, Su et al. 2006)，T lymphocytes (Song, Mahidhara 
et al. 2004)，smooth muscle cells (Ollinger, Bilban et al. 2005) and breast 
cancer cells (Hill, Pereira et al. 2005), while some reports have 
demonstrated that HO-1 stimulates the proliferation of numerous types of 
cells, such as epidermal keratinocytes (Clark, Green et al. 1997), epidermis 
" (Hanselmann, Mauch et al. 2001), and vascular endothelium (Deramaudt, 
Braunstein et al. 1998). Our studies in chapter 3 indicate that HO-1 is a 
cytoprotective factor in MKN28 and MKN45 in response to 5-FU 
treatment, providing a positive growth signal in both types of cells under 
the stress of the chemotherapeutic agent. The experiments in this chapter 
demonstrated that the inhibition of HO-1 by ZnPP was able to enhance the 
GO/Gl arrest caused by 5-FU, blocking cancer cells from going into the 
G2/M-phase, and eventually reduced mitosis. Moreover, the inhibition of 
HO-1 also increased the number of cells to escape from the normal cell 
cycle and rendered the cells to undergo apoptosis, which was consistent 
with our previous TUNEL results. . 
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In order to investigate how the inhibition of HO-1 enhances cell apoptosis 
caused by the chemotherapeutic agent 5-FU in gastric cancer cells and 
which apoptosis pathway is involved, we have studied the mitochondrial 
membrane potential. It is known that the reduction of the mitochondrial 
membrane potential is highly associated with the increased permeability of 
the mitochondrial membrane, which is followed by the release of 
apoptosis-relating molecules such as apoptosis-inducing factor (AIF), 
endonuclease-G, Smac/Diablo, and cytochrome c. Thus the mitochondrial 
membrane potential has been used as a recognized marker for early 
apoptosis detection (Vayssiere, Petit et al. 1994; Zoratti and Szabo 1995; 
Green and Reed 1998). We first examined the mitochondrial membrane 
potential of both gastric cancer cells and found the mitochondrial 
membrane potential was significantly reduced after the treatment of 5-FU 
plus ZnPP in MKN28 and MKN45 at 6h and 3h respectively after the 
treatment, indicating that apoptosis induced by co-treatment with 5-FU and 
ZnPP is involved in the mitochondria-dependent pathway. Furthermore, 
contrast to the significant alteration of the mitochondrial membrane 
potential in both types of cells treated with the combination of 5-FU and 
ZnPP, there was no obvious alteration detected in the cells treated with 
either 5-FU or ZnPP alone for the same length of time. This result may be 
interpreted as that the inhibition of HO-1 can shorten the time needed for 
98 
5-FU alone to trigger the permeabilization of the mitochondrial membrane 
and subsequently induce apoptosis. 
Since the mitochondria-dependent apoptosis was involved in the treatment 
with 5-FU plus ZnPP in both cell lines, we examined several of the 
mitochondrial-related apoptotic proteins in order to better understand the 
underlying mechanism. We found that, compared with the control group or 
the 5-FU group, the expression of pro-caspase-3 was evidently reduced 
after the treatment with 5-FU plus ZnPP, indicating that caspase-3 was 
significantly activated by 5-FU and HO-1 inhibitor ZnPP in combination. 
This finding demonstrated that a caspase-dependent pathway was involved 
in apoptosis induced by the co-treatment with 5-FU and ZnPP in MKN28 
and MKN45 cells. Our results also showed that the expression of pro-
caspase-3 in both cells was not obviously reduced after the treatment with 
5-FU alone for 24h, while the reduction of pro-caspase-3 was evidently 
shown after the combined treatment of 5-FU and ZnPP. This indicates that 
the activation of caspase-3 by 5-FU required longer than 24h to achieve in 
both cells and the inhibition of HO-1 not only increases the numbers of 
apoptotic cells induced by 5-FU but also hastens the time of apoptosis 
occurrence. 
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Cytochrome C in the cytosol was increased after the combined treatment 
with 5-FU and ZnPP in MKN45, indicating that cytochrome c was 
released into the cytosol from the mitochondria after the reduction of the 
mitochondrial membrane potential in response to the stimulation of the 
combined treatment in MKN45 cells. One of the main consequences of the 
mitochondrial cytochrome c release is the activation of caspase-3(Li, 
Nijhawan et al. 1997). However, the translocation of cytochrome c in 
MKN28 was not obviously detected. This finding may suggest that either 
the anti-cytochrome c antibody used for Western blotting is not sensitive 
enough in MKN28 or some other unknown apoptotic proteins rather than 
cytochrome c participate in apoptosis followed by the activation of 
caspase-3 in MKN28. Nevertheless it is generally considered that 
cytochrome c is essential for the activation of caspase-3 (Li, Nijhawan et 
al. 1997; Zou, Henzel et al. 1997; Mancini, Nicholson et al. 1998). 
The translocation of AIF from the mitochondria to the cytosol was 
detected in MKN28 after the combined treatment with 5-FU and ZnPP. It 
is well known that AIF has the unique property of inducing apoptosis-like 
change in purified nuclei in vitro without participation of any caspase(Liu, 
Kim et al. 1996; Zamzami, Susin et al. 1996) and apoptosis induced by 
AIF can be inhibited by the broad-spectrum caspase inhibitor Z-VAD-fmk 
(Susin, Lorenzo et al. 1999). AIF is released from the mitochondria when 
100 
the mitochondria become protein permeable in response to apoptotic 
signaling, and translocates via the cytosol to the nuclei, where it binds to 
DNA and triggers apoptosis(Susin, Zamzami et al. 1996). AIF has been 
recognized as a hallmark of caspase-independent apoptosis (Daugas, Susin 
et al. 2000). Our results show that AIF is involved in apoptosis induced by 
the co-treatment in MKN28 cells, implying it occurs at least partly via a 
caspase-independent pathway. However, there was no obvious change of 
AIF in MKN45 detected. Such different findings may be due to the 
different status of p53 in MKN28 and MKN45. p53 is a key upstream 
initiator of the cell death process. It can induce the release of cytochorome 
c from the permeabilized mitochondria and activate caspases-dependent 
- apoptosis (Cregan, MacLaurin et al. 1999; Keramaris, Stefanis et al. 2000). 
In MKN45, the wild type of p53 functions as an effective initiator in the 
caspase-dependent apoptosis which can be induced by the combined 
treatment whereas such an initiator is unavailable in MKN28 due to the 
mutant status of p53. Therefore, the caspase-independent pathway should 
be complementarily activated in MKN28 to induce apoptosis via the AIF-
dependent mechanism. However, further investigation is needed to verify 
this explanation. We could transfect with p53 gene into MKN28 and 
explore whether the AIF-dependent apoptosis pathway is still activated. 
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In conclusion, we have demonstrated in this study that 5-FU in 
combination with HO-1 inhibitors induced apoptosis in MKN45 cells in a 
caspase-dependent pathway through the collapse of the membrane 
potential of the mitochondria, followed by the release of cytochrome c and 
the activation of caspase-3. Apoptosis in MKN28 cells is probably induced 
by the combined treatment in two pathways: one is a caspase-3-related 
pathway, which is similar to that observed in MKN45, and the other is a 
caspase-independent pathway, which is associated with the release of AIF 




Summary and future prospects 
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5.1. Summary 
5.1.1. The inhibition of HO-1 enhances the sensitivity of gastric cancer 
cells to 5-FU 
Two human gastric cancer cells (MKN28 with mutant p53 and MKN45 
with wild p53) were used for the experiments to detect the effect of HO-1 
inhibition on 5-FU treatment. HO-1 inhibitor ZnPP can reduce cell 
viability of both types of cells and enhances the reduction of cell viability 
caused by 5-FU in both cells. The inhibition of HO-1 also enhances the 
ability of 5-FU to suppress cell growth through cell cycle arrest. Moreover, 
apoptotic cells induced by 5-FU were increased after the inhibition of HO-
1. All of these data demonstrate that HO-1 plays a cytoprotective role in 
the anti-gastric cancer treatment by 5-FU and that the inhibition of HO-1 
strengthens the cytotoxicity of 5-FU to both gastric cancer cells. The 
sensitivities of both gastric cancer cells to 5-FU can be greatly enhanced 
by the inhibition of HO-1. MKN45 cells with wild p53 are more sensitive 
to the treatment of 5-FU than MKN28 cells with mutant p53, which is 
consistent with general reports about p53 as an effective initiator of 
apoptosis. However, the additive effects of HO-1 inhibitor and 5-FU on 
both cells are not significantly different. 
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5.1.2 Apoptosis induced by 5-FU plus HO-1 inhibitor ZnPP is through 
a mitochondrial-related pathway in MKN28 and MKN45. 
Apoptosis induced by intracellular signals has been mainly included three 
pathways: Fas and tumor necrosis factor-a receptors-dependent pathway 
initiated by extrinsic signaling, mitochondria-dependent pathway and 
endoplasmic reticulum(ER)-dependent pathway initiated by intrinsic 
signaling. The reduction of the mitochondrial membrane potential (A中;„) 
can be regarded as a key feature of apoptosis which is in a mitochondria-
dependent pathway. Our results showed the mitochondrial membrane 
potential (A中;„) was significantly reduced after the treatment with 5-FU in 
combination with the inhibition of HO-1 in MKN28 and MKN45, while 
this alteration was not detected in cells treated with 5-FU or ZnPP alone 
after the same time. Therefore, we can conclude that apoptosis induced by 
5-FU plus ZnPP in both types of cells is via a mitochondria-dependent 
pathway and the inhibition of HO-1 can shorten the apoptosis-inducing 
time needed by the 5-FU.. 
Apoptosis induced 5-FU plus ZnPP occurs eaarlier in MKN45 than that in 
MKN28 as the reduction of A^P^ by the combined treatment can be 
detected in MKN28 at 6h after the treatment whereas in MKN45 at 3h 
after the treatment. 
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5.1.3 5-FU plus ZnPP induces apoptosis in a caspase-dependent 
pathway in MKN45 while in both caspase-dependent and caspase-
independent pathway in MKN28. 
Mitochondrial apoptosis pathway consists of caspase-dependent pathway 
and caspase-independent pathway. Caspase-3 is an important executioner 
caspase involved in a caspase-dependent apoptosis. 5-FU and ZnPP in 
combination activate caspase-3 in both types of cells, demonstrating that 
apoptosis is, at least partly, via a caspase-dependent pathway in MKN28 
and MKN45 cells. 
Cytochorome c was translocated into the cytosol in MKN45 after the 
combined treatment, implying that the combined treatment triggered 
apoptosis in MKN45 in a caspase-dependent pathway which is involved in 
both caspase-3 and cytochrome c. 
As AIF is identified as a key protein participating in a caspase-independent 
apoptosis, the result that the treatment of 5-FU plus ZnPP in MKN28 
triggered the translocation of AIF into the cytosol indicated that a caspase-
independent pathway was involved in the apoptosis induced by 5-FU and 
ZnPP in combination and this pathway was AIF-dependent. 
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5.1 Future prospects 
The increased expression of HO-1 was observed in gastric cancers with the 
treatment of 5-FU and the inhibition of HO-1 enhanced the sensitivity of 
gastric cancer cells to 5-FU in our experiments. These findings indicate 
that HO-1 may be a useful target in the anti-gastric cancer chemotherapy 
and its inhibitors could possibly be used as an auxiliary in combination 
with the chemotherapeutic agents to treat gastric cancers. However, at 
present our findings are all obtained in vitro cultured MKN28 and MKN45 
cells. Therefore, it will be important to confirm the results in other gastric 
cell lines as well as in vivo models of gastric cancer. 
Apoptosis in a mitochondria-dependent pathway was involved and 
enhanced by the combined effect of 5-FU and ZnPP on anti-gastric cancers 
in our experiments, indicating that the mitochondria play a key role in the 
combined treatment. Although the mitochondrial-dependent pathway is a 
main apoptotic pathway induced by a various intracellular signals, there 
are two other identified pathways: Fas and tumor necrosis factor-a 
receptors-dependent pathway initiated by extrinsic signaling and 
endoplasmic reticulum(ER)-dependent pathway initiated by intrinsic 
signaling. It is still needed for further investigation to test whether the two 
pathways are possibly involved in the combined treatment with 5-FU and 
ZnPP in gastric cancer cells. 
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The treatment of 5-FU in combination with the inhibition of HO-1 
induced a caspase-dependent apoptosis pathway through the collapse of 
the membrane potential of mitochondria, followed by the release of 
cytochrome c (not confirmed in MKN28 in our experiments) and the 
activation of caspase-3 in MKN28 and MKN45. There was another 
apoptotic pathway involved in MKN28 treated with 5-FU plus ZnPP, 
which is a caspase-independent pathway with the release of AIF from the 
increased permeable mitochondrial membrane to the cytosol and the 
nucleus. The differences between the apoptotic pathways involved in the 
two gastric cancer cell lines may be due to the different status of p53. 
However, further experimental evidence is necessary to support this 
opinion. 
Since apoptosis is an unarguably complicated process, much more work at 
fundamental level is still needed to explore the regulation of apoptosis as 
well as other underlying apoptotic proteins involved in the treatment of 5-
FU in combination with the inhibition of HO-1, and to further understand 
the molecular basis responsible for the sensitivity of gastric cancer to 5-FU 
by the inhibition of HO-1. It is evident by our study that HO-1 inhibitors 
are promising adjuvants in combination with chemotherapeutic agents in 
the treatment of gastric cancer. 
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